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 The growing incidences of coronary artery bypass graft surgeries have triggered a 
need to engineer a viable small diameter blood vessel substitute. An ideal tissue 
engineered vascular graft should mimic the microenvironment of a native blood vessel, 
while providing the adequate compliance post-implantation. Current vascular graft 
technologies lack the ability to promote vascular ECM deposition, leading to a 
compliance mismatch and ultimately, graft failure. Hence, in order to engineer suitable 
vascular grafts, this thesis describes the synthesis and characterization of novel elastin 
mimetic peptides, EM-19 and EM-23, capable of promoting vascular ECM deposition 
within a poly(ethylene glycol) diacrylate (PEG-DA) hydrogel. By combining the material 
properties of a synthetic and bio-inspired polymer, a suitable microenvironment for cell 
growth and ECM deposition can be engineered, leading to improved compliance.  
As such, characterization of EM-19 and EM-23 was conducted in human vascular 
smooth muscle cell (SMC) cultures, and the peptides self-assembled with a growing 
elastic matrix. After grafting the peptides onto the surface of PEG-DA hydrogels, EM-23 
increased SMC adhesion by 6000% over PEG-RGDS hydrogels, which have been the 
gold standard of cell adhesive PEG scaffolds. Moreover, EM-23 grafted surfaces were 
able to promote elastin deposition that was comparable to tissue cultured polystyrene 
(TCPS) surface even though TCPS had roughly 4.5 times more SMCs adhered. Once 
translated to a 3D model, EM-23 also stimulated increased elastin deposition and 
improved the mechanical strength of the scaffold over time. Moreover, degradation 
studies suggested that EM-23 may serve as a template that not only promotes ECM 
 xvii
deposition, but also allows ECM remodeling over time. The characterization studies in 
this thesis suggest that this peptide is an extremely promising candidate for improving 
vascular ECM deposition within a synthetic substrate, and that it may be beneficial to 






The American Heart Association estimates that the number of coronary artery 
bypass graft surgeries is expected to increase significantly in the next 5 years [1]. As 
such, there has been a heightened demand for an implantable blood vessel substitute 
capable of depositing vascular extracellular matrix (ECM) while providing the 
appropriate mechanical properties. Synthetic grafts have found long term success as large 
diameter arterial replacements; however, they fail significantly when implemented as 
small diameter substitutes. Therefore, this dissertation will describe and characterize the 
efficacy of elastin mimetic peptides in promoting vascular ECM deposition when 
incorporated within a biomaterial. The central hypothesis of the work presented in this 
thesis is that more compliant vascular grafts can be engineered from a combination of 
synthetic and bio-inspired materials.  
 
1.2 Cardiovascular Diseases 
 
Cardiovascular related diseases are the number one cause of patient morbidity in 
the United States, and the number of patients diagnosed with various cardiovascular 
diseases is expected to increase in the coming years [1]. Atherosclerosis, narrowing of the 
blood vessels due to plaque buildup, is the most common form of cardiovascular disease 
[1, 2]. According to the American Heart Association, the majority of patients diagnosed 
with a form of atherosclerosis have weakened arterial walls that eventually lead to 
cardiac arrest [1]. Furthermore, as the disease progresses over time, the blood flow 
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dynamic within the cardiovascular system changes significantly, causing decreased blood 
flow and greater arterial wall pressures [2-4].  
Patients diagnosed with atherosclerosis undergo coronary artery bypass graft 
surgery, in which blocked arteries with plaque buildup are rerouted with a substitute 
saphenous vein or internal mammary artery in order to alleviate the arterial pressure and 
increase blood flow [5-8]. Furthermore, patients undergoing such a surgery frequently 
require multiple bypasses, and for many patients, multiple bypasses are not possible 
because the donor supply of arterial substitutes are diseased themselves or are in a state 
of trauma due to a previous surgery [2-4, 9]. As a result, there is a significant demand for 
a viable blood vessel substitute having an internal diameter less than 6 mm [10, 11]. To 
address this demand, this thesis will investigate a novel material derived from synthetic 
and bio-inspired sources as a potential candidate for a blood vessel substitute. The central 
hypothesis of this work lies in engineering suitable vascular grafts by combining the 
advantages of utilizing materials from synthetic and bio-inspired sources. 
 
1.3 Anatomy of a Blood Vessel 
A blood vessel is comprised of three different layers: tunica intima, media, and 
adventitia (Figure 1.1).  The innermost layer, tunica intima, comprises of a monolayer of 
endothelial cells (ECs) that are in direct contact with blood. The ECs inhibit platelet 
activation and create a non-thrombotic blood contacting surface by secreting small 
molecules such as nitric oxide [12, 13]. The medial layer, tunica media,  is comprised of 
smooth muscle cells (SMCs), while the outermost layer, tunica adventitia, is primarily 
comprised of adventitial fibroblasts [4]. Also, an internal elastic lamina is found between 
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the intimal and medial layers while an external elastic lamina is found between the 
medial and adventitial layers. Both elastic laminas provide the adequate compliance 
necessary for a blood vessel to function properly in vivo. Compliance is an important 
property in characterizing the ability of a material to undergo volumetric changes when 
subjected to large changes in pressure as the heart pumps blood throughout the body [14]. 
The SMCs in the tunica media secrete elastin and organize themselves in a 
circumferential orientation providing the necessary compliance for a blood vessel in vivo 
[5, 15, 16].  
 
Figure 1.1. A blood vessel is comprised of three different layers: tunica intima, media, and adventitia. 
The intimal layer is in contact with lumen and contains endothelial cells, whereas the medial and adventitial 
layers contain smooth muscle cells and fibroblasts, respectively. There is an internal elastic lamina between 
the intimal and medial layer; an external elastic lamina exists between the medial and adventitial layer. 
Both layers provide adequate elasticity and compliance to a blood vessel. 
 
A significant challenge in vascular graft engineering is the ability to mimic the medial 
layer of a blood vessel within the synthetic substitute [2, 11]. An ideal biocompatible 
substitute should not only have a non-thrombotic intimal layer, but also an elastic layer 
that provides structural compliance while allowing for the development of a functional 














synthetic and bio-inspired sources that is capable of promoting ECM deposition and may 
potentially lead to the engineering of more compliant vascular grafts. A poly(ethylene 
glycol) diacrylate (PEG-DA) hydrogel was chosen as the synthetic polymer for its 
biocompatible and hydrophilic properties that limit platelet adhesion and thrombosis 
function. Two different peptides, inspired by elastin, were chosen to help promote 
vascular ECM deposition within the PEG-DA hydrogels. By combining the strengths of 
these two materials, a more suitable microenvironment for engineering vascular tissues 
may be achieved.  
 
1.4 Tissue Engineering of Vascular Grafts 
For the past two decades, the field of tissue of engineering has grown considerably 
and is the most promising alternative for engineering a viable blood vessel substitute. By 
definition, “the goal of tissue engineering is to repair or replace damaged tissues within 
the body by providing functional cells and scaffolds to the areas of need” [19]. Tissue 
engineering combines engineering and life science principles to fabricate viable 
biological substitutes aimed at repairing or replacing damaged organs or tissues [20-22]. 
The general approach for tissue engineering lies in seeding autologous cells within a 
three-dimensional (3D) scaffold in vitro, allowing the scaffold to promote ECM 
deposition in vivo, and having the cells completely resorb the 3D scaffold space [4, 5, 23-
25].  
Indeed the “holy grail” in tissue engineering is the fabrication of a viable vascular 
graft and in order to be successful, a few design considerations must be implemented [2, 
11]. First, an ideal scaffold should be biocompatible and mimic the microenvironment of 
 5
a native blood vessel while limiting non-specific protein adsorption, which leads to a 
reduced inflammatory response post-implantation. The scaffold must also contain proper 
biochemical cues that allow the encapsulated cells to remodel the scaffold and eventually 
replace the entire conduit with a natural ECM [26].  
Second, the choice of cell types to seed and cell orientation within the scaffold is 
critically important [27-30]. A native blood vessel is comprised of three different cell 
types: ECs, SMCs, and fibroblasts [16, 30]. Each cell type has its own distinct function 
within the blood vessel. For example, ECs line themselves along the lumen, are capable 
of withstanding greater changes in shear stresses, and provide a non-thrombotic surface. 
On the other hand, SMCs have a concentric alignment within the medial layer and are 
responsible for synthesizing the elastin that provides compliance to a blood vessel. 
Finally, the fibroblasts, found in the outermost layer of a blood vessel, have an axial 
alignment with the blood vessel and provide structural integrity by secreting vascular 
collagen [16, 30, 31]. Ideally, an engineered vascular graft should have all three cell 
types; however, co-culturing these cells within a construct presents a significant 
challenge.  
Further, the mechanical properties of the scaffold should match that of a native blood 
vessel before implantation. The mechanical strength of a native blood vessel is 
anisotropic by nature, exhibiting high elasticity at low pressures, yet providing greater 
stiffness at high pressures [32]. A synthetic polymeric scaffold will allow for better 
control over the mechanical properties, however, synthetic scaffolds lack the necessary 
cues to promote a microenvironment mimicking a blood vessel [33]. On the other hand, a 
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scaffold engineered from naturally occurring polymers such as collagen, although 
biodegradable, will have compliance that falls short of a native blood vessel [34]. 
Next, the scaffold must also have easy off-the-shelf availability. A big limitation in 
engineering vascular grafts is the long processing times required before implantation 
[30]. For example, Isenburg et al. attempted to engineer ready-to-use vascular grafts in a 
bioreactor using key ECM components such as elastin. However, the short maturation 
times yielded grafts that had low mechanical strengths and stability [35]. Regardless of 
the choice of material or cell type used to fabricate the vascular graft, current technology 
limits the ability of vascular grafts to have quick off-the-shelf availability.  Also, one of 
the key requirements of an engineered vascular graft is that the final scaffold must be 
functional as soon as it is implanted [36].  
As such, this thesis attempts to address the aforementioned design considerations by 
engineering scaffolds for vascular grafts using a combination of synthetic (PEG-DA) and 
bio-inspired (elastin mimetic) materials. By utilizing the strengths of each class of 
material, scaffolds can be engineered that are not only compliant, but also mimic the 
microenvironment of a native blood vessel. The rationale behind this work comes from 
previous studies that have investigated the strengths and weaknesses of different 
synthetic and natural materials for vascular graft applications. 
1.4.1 Synthetic Materials for Engineering Vascular Grafts 
For decades, synthetic vascular grafts engineered from Dacron or extended 
poly(tetraflouroethylene) (ePTFE) have found long term success as viable large diameter 
blood vessel replacements (i.e. >6 mm) [2, 3, 37]. Synthetic materials offer a greater 
degree of control over intrinsic properties such as molecular weight, porosity, and 
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mechanical strength [38]. However, these grafts fail significantly when implemented as 
small diameter replacements due to their inability to provide the necessary cues to 
support cell adhesion and ECM deposition. Moreover, once implanted, the inability of the 
synthetic grafts to provide a non-thrombotic surface results in a drastic decrease in graft 
diameter, leading to, hyperplasia, occlusion and compliance mismatch with native 
arteries[10, 11, 39-41].  
 Similarly, poly(glycolic acid) (PGA) is another example of  a synthetic material 
routinely used for engineering vascular grafts. The inherent biocompatibility and 
biodegradability of PGA makes this polymer highly attractive for engineering vascular 
grafts [16, 42-47]. However, PGA based scaffolds degrade quickly and secrete acidic 
byproducts that may have cytotoxic effects over a long period of time. The fast 
degradation of PGA scaffolds in vivo may alter the mechanical properties of the graft too 
quickly, leading to inadequate burst strengths and compliance [26]. PGA based scaffolds 
also do not promote ECM deposition over time, a key design criteria for engineering 
viable blood vessels.  
Niklason et al. engineered the first autologous vascular graft made entirely of PGA 
conditioned in a bioreactor [48]. SMCs were cultured on the PGA scaffold followed by 
EC seeding on the lumen of the scaffold. The final construct was allowed to mature in 
physiological flow conditions for 8 weeks after which burst pressures of 2150 ± 709 mm 
Hg were achieved. In comparison, the burst pressure of saphenous vein is 1680 ± 307 
mm Hg. Although promising, the inherent lack of elastin within the scaffold and the long 
culture time were the major limitations to this system [26].  
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The first clinical application of a vascular graft engineered from PGA was conducted 
in 2001 by Shin’oka et al. [49]. Polymeric vascular grafts fabricated from a combination 
of poly(caprolactone) (PCL) and PGA fused with autologous venous and bone marrow 
cells were implanted in a 4 year old girl. After a 5 year follow-up study, no complications 
post-implantation were reported, including no signs of thrombosis and stenosis [25, 50, 
51]. However, the use of bone marrow cells within these grafts presents a greater risk of 
cell differentiation and tumor formation [26]. The grafts were also implanted in low-
pressure circulation of 20 mm Hg compared to a high pressure circulation system within 
the coronary system of 140 mm Hg [11]. Further, long term effects, such as calcification, 
must also be investigated. Calcification is defined as the deposition of crystalline calcium 
phosphate that occurs in vivo, causing severe deterioration and stiffening, which can lead 
to graft failure [52]. 
Alternatively, vascular grafts fabricated from poly(lactic acid) (PLA) have also 
shown to be promising blood vessel replacements, having slower degradation kinetics 
than PGA-based scaffolds [26, 53, 54]. The slower degradation of PLA scaffolds allows 
the final conduit to retain higher mechanical strength over a longer period of time. Kim et 
al. engineered vascular grafts from a combination for PLA and PGA polymers and 
conditioned the grafts in a dynamic flow environment [55, 56]. Rat aortic SMCs were 
seeded within the scaffold under dynamic flow conditions and elastin biosynthesis was 
quantified, the results showing that the choice of polymer was important in elastin 
production during the dynamic conditioning of the scaffold. In a different study, Wang et 
al. electropun PLA/silk fibroin-gelatin composite scaffold and were able to demonstrate 
burst pressures of 1596 ± 20 mm Hg [57]. However, these grafts lacked elastin 
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deposition, as PLA-based vascular grafts also lack the ability to promote ECM deposition 
over time.  
 Polyurethanes (PUs) are another class of materials routinely used to fabricate 
small diameter vascular grafts. With its natural elasticity and ease of handling, PU-based 
vascular grafts have become the current gold-standard for engineering synthetic vascular 
grafts [10, 33, 58-60]. For example, Jun et al. engineered microporous PU scaffolds with 
EC adhesive ligands and  observed increased endothelialization and decreased platelet 
aggregation [61]. The scaffolds also showed increased mechanical strength in comparison 
to microporous PU urea scaffolds without EC adhesive ligands. Further, Rashid et al. 
modified PU with a fibronectin-like protein and engineered a vascular graft capable of 
increasing SMC proliferation [62].  
 Similarly, Ratcliffe et al. successfully engineered a PU based vascular graft under 
pulsatile flow conditions leading to comparable mechanical strengths to native blood 
vessels [36]. In a separate study, Grenier et al. pre-coated PU surfaces with fibronectin 
and observed higher SMCs adhesion and infiltration within the 3D scaffold in 
comparison to Matrigel-coated PU scaffolds [63]. However, neither condition showed 
any significant differences in elastin or collagen production. Further, a major drawback 
and limitation in PU scaffolds is the involvement of toxic precursor, diisocyanates, in the 
overall synthesis [64].  
Although synthetic substitutes offer the advantage of fine-tuning their intrinsic 
properties, a major disadvantage is the generation of foreign body response over a long 
period of time [11, 19]. Furthermore, the synthetic materials discussed above are limited 
as blood vessel substitutes because of their inability to behave as ECM mimics [10, 17, 
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18, 65, 66]. As an alternative approach, this thesis will investigate the use of PEG-DA 
hydrogels as the synthetic material for engineering vascular grafts.  
Hydrogels are a class of materials that are biocompatible, possess higher water 
content, are fabricated under mild conditions, and facilitate improved oxygen and 
essential nutrient transport [67-73]. Although these gels serve as blank slates and lack any 
biological cues to promote normal cell functions, they can be easily tailored with 
adhesive peptides that can promote cell attachment, proliferation, and ECM deposition 
[74]. Hydrogels are an example of 3D systems that are composed of crosslinked networks 
that behave as ECM mimics and hence, utilizing them as scaffold materials for tissue 
engineering vascular grafts is highly attractive [75]. Specifically, PEG derivatized 
hydrogels have shown to be biocompatible, reproducible, and easily allow fine tuning of 
their mechanical properties [76, 77]. 
PEG is a well-characterized polymer that is FDA approved for a wide range of 
biomaterial applications [68, 78-80].  Moreover, PEG hydrogels limit nonspecific protein 
adsorption while reducing platelet aggregation and thrombosis [81-85]. In addition to 
being resistant to nonspecific protein adsorption, PEG-DA hydrogels are optically 
transparent, highly elastic, and their mechanical properties are easily tunable [81]. The 
intrinsic properties of PEG-DA hydrogels can also be fine-tuned to achieve different 
elastic responses by varying the molecular weight or polymer concentration in solution 
[84]. Moreover, hydrogels from diacrylate derivatized PEG (PEG-DA) have shown to be 
promising models for scaffold materials [82, 84-86]. In the presence of a photoinitiator 
and UV light, the free acrylate groups on PEG-DA crosslink to form a hydrogel [68, 87, 
88]. Also, PEG-DA hydrogels can be tailored with adhesive peptides to drive cell 
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adhesion for specific cell types [82, 86, 89]. For example, Gobin et al. conjugated the 
peptide sequence valine-alanine-proline-glycine (VAPG) onto the surface of a PEG-DA 
hydrogel with a monoacrylate PEG derivative, which facilitated vascular SMC adhesion 
and spreading [86].  
 Although PEG-DA is a biocompatible polymer, it is not biodegradable [69, 90]. 
With protein engineering evolving in the past few years, specific peptide sequences can 
now provide the cues necessary not only for cell adhesion, proliferation, migration, and 
matrix deposition, but also for scaffold degradation. The work presented in this thesis 
discusses different elastin mimetic peptides that can promote vascular ECM deposition 
within a PEG-DA hydrogel. The elastin mimetic peptides serve as the bioactive moieties 
intended to increase elastin within the scaffold, whereas the PEG-DA hydrogels serve to 
provide structural integrity. In comparison, previous studies have also investigated the 
strengths and weaknesses of vascular grafts engineered from only natural sources such as 
collagen and these will be discussed in the subsequent section. 
1.4.2 Natural Material for Engineering Vascular Grafts 
 Many different approaches have been made to engineer vascular grafts from 
natural polymers. For example, decellularized tissues have gained considerable attention 
for engineering vascular grafts in which the native ECM is preserved within the final 
construct [91-95]. Many groups have utilized decellularized small intestinal submucosa 
as vascular graft constructs, showing high patency rates and feasibility [96-98]. 
Furthermore, Derham et al. used decellularized porcine aorta as scaffold material for 
small diameter vascular grafts and observed similar ultimate tensile strength and 
compliance to native tissues [99]. In another study, decellularized human umbilical 
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arteries were implanted in rats as small diameter blood replacements [100]. The vascular 
grafts showed high patency and did not show any signs of thrombosis or stenosis 8 weeks 
after implantation [101].  
 However, the source material for decellularized tissues comes from either 
allogeneic (another animal of the same species) or xenogeneic (an animal of another 
species) sources. As a result, there lies a great risk of disease transmission and immune 
response [26]. Furthermore, the harsh conditions used to decellularize tissues could alter 
the ECM structure, thus making it difficult for large batch preparations [102]. 
Decellularized tissues show great potential; however, little information is available for 
their long term stability [19, 33, 101, 103].  
On the other hand, previous studies have also investigated engineering vascular 
grafts from collagen and elastin, the critical ECM components found in a blood vessel [4, 
104, 105]. Collagen, for example, gels readily under physiological conditions and has 
been a primary natural source material for vascular grafts [4, 26, 106, 107]. Weinberg and 
Bell utilized collagen gels as scaffold materials for vascular grafts; however, the final 
construct was found to be too weak for use as a blood vessel substitute [108]. The 
construct also lacked elastin formation, which is critical for graft compliance [19]. This 
pioneering study, however, led to many different strategies that utilized natural polymers 
as materials for vascular graft engineering. There have been many attempts to increase 
the mechanical strength of collagen gels using different strategies such as providing a 
Dacron support to increase the gel stiffness, glycation to chemically increase collagen 
stiffness, using degradable meshes as sleeves, and mechanically conditioning the gels 
[109-116]. Although these techniques have increased the mechanical properties of 
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collagen, the final constructs still fall short of the required strength for a blood vessel 
substitute [26]. Furthermore, collagen based vascular grafts also lack the presence of 
elastin [4, 16]. 
Elastin is a 70 kDa insoluble protein found in the vascular ECM from which 
blood vessels derive their high compliance and tensile strengths [117-119]. The protein is 
an important asset to the overall vascular ECM as it makes up about 50% of its dry 
weight [104, 105]. Elastin also inhibits dynamic tissue creep and fibrocellular pathology 
[120, 121]. Finally, elastin is a key factor for promoting SMC proliferation and also helps 
regulate SMC migration within the medial layer of a blood vessel [122, 123].  
Structurally, elastin has alternating hydrophobic and hydrophilic domains [124]. 
The hydrophobic domain is rich in nonpolar amino acids such as V, P, G, and A. These 
amino acids are often present as four to six repeating peptides such as GGVP, GVGVP, 
VGVAPG [125]. The hydrophilic domain, on the other hand, is rich in lysine (K) or 
alanine. The lysine residues are often interspersed between the alanine residues, playing a 
significant role in the crosslinking of tropoelastin, a 72 kDa elastin precursor, to form 
insoluble elastic fibers [126]. Moreover, peptide sequences such as VAPG and VGVAPG 
have been specifically shown to have chemotactic activity against monocytes, fibroblasts, 
and tumor cells [127-130]. The hexapeptide sequence VGVAPG interacts with SMCs via 
the cell surface-bound receptor called the elastin binding protein (EBP), leading to 
different chemotactic responses from cells such as vasorelaxation and platelet anti-
aggregation [127, 130-132]. Elastic fibers have a half-life of 70 years and elastin is one of 
the most stable proteins found in the vascular ECM [133]. 
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Elastin is a critical component of a blood vessel and many researchers have 
focused on improving elastin biosynthesis within biomaterials by incorporating various 
growth factors, providing a mechanical stimuli, or engineering scaffolds from a 
combination of soluble elastin and collagen [112, 116, 120, 134-137]. Although 
promising, many elastin mimetic grafts lead to calcification post-implantation [138-141]. 
As a result, there has been a greater push to engineer elastin-like proteins capable of 
promoting elastin deposition within a synthetic scaffold [142-145]. For example, Martin 
et al. chemically crosslinked elastin-like polymers to engineer macroporous 3D 
constructs for tissue engineering applications and found favorable EC cell adhesion 
[146]. The study concluded that by controlling the porosity of the construct, more robust 
scaffolds can be engineered.  
Moreover, recombinant elastin block copolymers have also gained considerable 
attention in engineering 3D constructs that have properties comparable to native elastin 
[147]. For example, Nagapudi et al. engineered elastin-like polypeptides using 
recombinant techniques and found similar viscoelastic behavior to native elastin [148]. 
However, the techniques described above are limited by their long processing times and 
the high costs associated in engineering the construct. As such, this dissertation describes 
the synthesis and characterization of novel elastin mimetic peptides capable of promoting 
vascular ECM deposition within a synthetic scaffold. The use of these peptides provides 





1.5 Synthetic and Natural Polymers for Engineering Vascular Grafts 
The different strategies discussed so far lack the ability to promote elastin 
production within a synthetic or natural material which leads to a compliance mismatch 
with the native blood vessels post-implantation. As such, to engineer compliant vascular 
grafts, different elastin mimetic peptides capable of promoting elastin deposition within a 
PEG-DA hydrogel were investigated in this thesis. The peptides were engineered based 
on the native structure of elastin as well as its ability to interact with the cells to induce 
more elastin production. 
In vivo, elastin is first secreted as tropoelastin by SMCs into the extracellular 
space. An important property of tropoelastin is the ability to self-assemble under 
physiological conditions, leading to the proper alignment of elastic fibers post 
crosslinking [149]. This self-assembly is primarily induced due to the presence of 
hydrophobic sequences on tropoelastin [150]. Tropoelastin is primarily synthesized in the 
rough endoplasmic reticulum of SMCs and undergoes posttranslational modification once 
secreted into the ECM [125]. Intracellularly, tropoelastin first binds to the EBP [149]. 
Once released from the cell surface, lysine residues on tropoelastin undergo spontaneous 
oxidative deamination under the presence of lysyl oxidase (LOX), a 50 kDa active 
enzyme also secreted by SMCs, resulting in tropoelastin aggregates [151, 152]. Four 
lysine groups from two tropoelastin molecules condense to form desmosine or 
isodesmosine (Fig. 1.2) [126, 153, 154].  
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Figure 1.2. Structure of desmosine and isodesmosine [126]. 
 
The EBP then chaperones the tropoelastin aggregate to adjacent microfibrils in 
the extracellular space, where the complex binds to galactosugars, causing a simultaneous 
release of the aggregates from the EBP [126, 149]. Once released, LOX further crosslinks 
the tropoelastin aggregates to form mature elastin fibers (Figure 1.3). Moreover, recent 
studies have suggested that tropoelastin may interact with the cell surface-bound integrin 
v3, and that this integrin may assist the EBP in elastogenesis [122, 155-158].  Previous 
studies also have utilized desmosine as an effective marker of to quantify the extent of 



























Figure 1.3. Elastin production involves a sequence of events involving the secretion of 
tropoelastin, which binds EBP on cell surfaces. Tropoelastin aggregates are then transported to adjacent 
microfibrils involved in elastin fiber assembly, and the EBP is recycled. The v3 integrin also binds the C-
terminal region of tropoelastin, playing a yet unknown role in the synthesis of mature elastin. 
 
However, a major drawback of elastin is that the protein is very hydrophobic and 
practically insoluble in aqueous media [161]. Post crosslinking, 75% of elastin is 
hydrophobic [126]. Furthermore, tropoelastin is hard to isolate due to its spontaneous 
reactivity to form elastin fibers [126, 162]. It is only after crosslinking that elastin 
achieves high elasticity, stability, tensile strength, and provides cellular cues for adhesion 
and proliferation. Incorporating elastin within a biomaterial for vascular graft 
applications has yielded poor results due to calcification post-implantation [138-141]. 
Nimni et al. hypothesized that improper fiber alignment of elastin and uncontrolled 
crosslinking of collagen and elastin within the scaffold could be possible reasons for 
calcification in constructs implanted in vivo [139].  
In this work, two different peptides were engineered to serve as elastin mimetics 
capable of self-assembling with cell-deposited ECM in vitro. Once incorporated within a 
PEG-DA hydrogel, the peptides will serve as templates for promoting vascular ECM 
deposition, leading to scaffold materials with enhanced biochemical cues and mechanical 
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properties. The elastin mimetic peptides investigated in this thesis contain the cell 
adhesion and crosslinking motifs found in native elastin, including a hydrophobic and 
hydrophilic domain. The central hypothesis is that the incorporation of an elastin mimetic 
peptide within a 3D scaffold can lead to cell adhesion and elastin crosslinking motifs 
serving as a template to facilitate an increase in elastin deposition within the scaffold. 
With increased elastin content, the final scaffold will have an appropriate ECM similar to 







Design and Characterization of Elastin Mimetic Peptide Sequences as Potential 
Templates for Vascular ECM Deposition 
 
2.1 Summary 
 Two different elastin mimetic peptides, EM-19 and EM-23, were engineered to 
serve as templates for self-assembling with cell-deposited elastin matrix. Both peptides 
contain the hexapeptide sequence VGVAPG that binds the surface bound EBP receptor 
and a crosslinking domain, resulting in a sequence that closely mimics the active motifs 
of tropoelastin. EM-23 also contains an RGDS domain, which has an affinity for cell 
surface integrins. Preliminary characterization indicated that both peptides have a 
disordered structure similar to soluble elastin and are able to self-assemble with a 
growing elastin matrix on a two-dimensional (2D) TCPS surface. The characterization 
studies also suggested that EM-23 has a higher affinity for integrins than for the EBP, 
suggesting the possibility that integrins play a significant role in elastin fiber assembly. 
To further clarify which integrins play a role in elastogenesis, total elastin content was 
quantified while blocking the activity of specific integrins. The results suggested that the 
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 The formation of a suitable ECM within a biomaterial still remains a significant 
challenge in the field of tissue engineering [73]. The ECM contains important growth 
factors and enzymes that help regulate cell migration, differentiation, and proliferation 
throughout the tissue [163]. Moreover, the ECM is comprised of several cell secreted 
proteins that serve as communication bridges between cells and the extracellular 
environment. A blood vessel, for example, is comprised of three different layers and each 
layer contains a unique ECM that provides compliance and structural integrity to the 
tissue. For example, the tunica intima of a blood vessel contains connective and 
anchoring filaments of fibrin-containing microfibrils and collagen [15, 164-166]. Tunica 
media contains a significant amount of elastin providing adequate compliance whereas 
tunica adventitia is rich in collagen and provides structural integrity to the blood vessel 
[15, 167-170]. Further, elastin accounts for approximately 50% of the dry ECM weight, 
and promotes SMC proliferation and migration throughout the intimal layer [104, 122, 
123, 133, 171-174]. 
 Elastin interacts with SMCs via a surface-bound receptor called the EBP [175]. 
The EBP forms a complex with intrinsic membrane proteins sialidase and 
carboxypeptidase A, and has high affinity for the hexapeptide sequence VGVAPG [130, 
176]. The binding of this sequence to the EBP has been shown to influence chemotaxis, 
vasorelaxation, and inhibit platelet aggregation [127, 172, 177]. Synthesis of elastin is a 
multi-step process in which tropoelastin is first secreted by SMCs and binds to the EBP 
[178]. Lysine residues on tropoelastin undergo oxidative deamination in the presence of 
LOX, forming tropoelastin aggregates. The EBP chaperones the aggregates to adjacent 
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microfibrils in the extracellular space, where it is proposed to interact with galactosugars 
on the microfibrils [136, 178-180]. After interacting with galactosugars, the EBP releases 
the aggregates for further crosslinking to form mature elastin fibers, while forming 
desmosine or isodesmosine at the crosslink sites [125, 126, 151, 152, 181, 182]. After 
crosslinking, the EBP is recycled via internalization and can bind with newly synthesized 
tropoelastin to facilitate further elastin fiber assembly [183]. Although this model has 
long been accepted as the basis for elastin production, recent evidence has also pointed to 
integrins playing an active role in elastin fiber assembly. Specifically, the integrin v3 
has been shown to interact with the C-terminal GRKRK motif of tropoelastin, alluding to 
the likelihood of this integrin somehow assisting the EBP in elastogenesis [155].   
 It is only after crosslinking that elastin achieves such high elasticity, stability, and 
tensile strength [8, 36, 133, 161, 184]. Moreover, the hydrophobicity of elastin makes it 
difficult to implement elastin as a biomaterial and as a result, many alternative 
approaches have been to engineer elastin-like proteins for vascular applications [8, 112, 
126, 139, 185-189]. For example, Nagpudi et al. utilized recombinant engineering to 
synthesize large elastin block copolymers that mimic native elastin [148]. The 
copolymers demonstrated a viscoelastic behavior similar to native elastin. In a separate 
study, Lee et al. also utilized recombinant DNA techniques to engineer elastin-like 
polypeptides capable of mimicking the active domains of elastin [186]. However, 
engineering protein expression can be costly, arduous, and require high processing times.  
This thesis describes the design and synthesis of two different hydrophilic elastin 
mimetic peptides, EM-19 (AAKAAKVGVAPGAAKAAKK) and EM-23 
(AAKAAKVGVAPGRGDSAAKAAKK), that were engineered for use as potential 
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templates for promoting vascular ECM deposition. Both peptides contain an EBP binding 
motif and a crosslinking domain that are native to tropoelastin. Furthermore, EM-23 
contains an additional integrin-binding domain, and may provide further insight to the 
role integrins play in elastin fiber assembly [190-193]. This chapter discusses the 
preliminary characterization of these peptides and investigates the potential role that each 
peptide may play in elastogenesis. 
2.3 Materials and Methods 
2.3.1 Circular Dichroism Studies  
Circular dichroism (CD) measurements were conducted on EM-19 and EM-23 to 
characterize the inherent structure of each peptide and compared to soluble human 
elastin. The measurements were performed by Alliance Protein Laboratories (Camarillo, 
CA). Peptides were dissolved in water at 0.2 mg/m and CD measurements were carried 
out on a Jasco J-715 spectropolarimeter using a 0.1 cm cell at room temperature and 
37ºC. The temperature was controlled by a PTC-348WI temperature controller and 
Peltier cell holder. The solvent spectrum was subtracted from the sample spectra and 
converted to the mean residue ellipticity (CD intensity per amino acid). 
2.3.2 Peptide Synthesis   
All materials and reagents for peptide synthesis were purchased from Advanced 
Automated Peptide Protein Technologies (AAPPTec; Louisville, KY). Six different 
peptides were synthesized using standard O-Benzotriazole-N,N,N’,N’-tetramethyl-
uronium-hexafluoro-phosphate (HBTU) coupling and fluorenylmethyloxycarbony 
(Fmoc) protection chemistry on an Apex 396 peptide synthesizer (AAPPTec, Louisville, 
KY). A 23 amino acid sequence (EM-23; AAKAAKVGVAPGRGDSAAKAAKK), 
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containing two cell adhesion motifs (VGVAPG and RGDS) as well as lysine rich 
crosslinking domains, was synthesized along with a 23 amino acid control peptide in 
which the VAPG sequence is scrambled and the RGDS sequence is left intact (EM-23S; 
AAKAAKVGVPAGRGDSAAKAAKK).  A 19 amino acid sequence (EM-19; 
AAKAAKVGVAPGAAKAAKK) and a 19 amino acid peptide in which the VAPG 
sequence is scrambled (EM-19S; AAKAAKVGVPAGAAKAAKK) were synthesized, 
omitting the RGDS motif completely in order to observe the importance of integrin 
binding. Both 23 and 19 amino acid sequences containing glycine residues in place of 
lysine were used to observe the importance of the hydrophilic crosslinking domain (EM-
23G; AAGAAGVGVAPGRGDSAAGAAGG; EM-19G, 
AAGAAGVGVAPGAGAAGG). Peptides were dialyzed using cellulose ester membrane 
tubing (MWCO 1000; Spectrum laboratories, Rancho Dominguez, CA).  The dialyzed 
peptides were then frozen and lyophilized overnight.  Peptides were characterized using 
mass spectrometry. RGDS was purchased (American Peptide Company, Sunnyvale, CA) 
and used as received. 
2.3.3 Cell Culture and Maintenance   
Human aortic smooth muscle cells (SMCs, passages 3-5; Invitrogen Inc., 
Carlsbad, CA), were used in this work. SMCs were maintained in Medium 231 
(Invitrogen Inc., Carlsbad, CA) supplemented with smooth muscle cell growth 
supplement (SMGS, Invitrogen Inc., Carlsbad, CA), 2 mM L-glutamine, 1 unit/ml 




2.3.4 Peptide Influence on Elastin and Desmosine Formation 
Elastin production and desmosine content were characterized in vitro after a 48 
hour incubation of each peptide with SMCs.  The 48 hour incubation period was chosen 
after initial experiments confirmed that the protein concentration following incubation 
with elastin mimetic peptides was well within the range of the commercially available 
assay used to quantify elastin. A stock solution of 5 µmol/ml of each peptide was made 
by dissolving in 10 mM HEPES buffered saline (HBS) at pH 7.4.  The solution was then 
sterile-filtered using 0.2 μm pore size nylon filters (Pall Life Sciences, Port Washington, 
NY).  A 24-well plate was seeded with 30,000 SMCs/cm2. Peptides were added to the 
cell suspensions during the seeding procedure at concentrations of 0.01, 0.1, or 1 
µmol/ml.  Peptides were directly seeded with the SMCs to investigate the efficacy of the 
peptides to self-assemble with the growing elastin matrix. Moreover, the integrins on the 
cell surface are utilized as cell adhesion motifs. In order to assess the role integrins play 
on elastin fiber assembly, it was important to seed the cells simultaneously with the 
peptides so that each peptide was able to fully interact with integrins before the cells fully 
adhered onto the TCPS surface.  
After 48 hours, the media was removed, the wells were thoroughly washed with 
phosphate buffered saline (PBS), and the well plates were frozen and lyophilized 
overnight. The contents of each well were hydrolyzed by adding 0.1 N NaOH and 
incubated for 1 hour at 100°C.  The resulting lysate was centrifuged at 8,000×g for 10 
mins and the supernatant containing the cell debris and soluble matrix components was 
removed.  The remaining insoluble elastin was suspended in 0.25 N oxalic acid and 
further hydrolyzed for 48 hours at 100°C.  Following the oxalic acid treatment, the 
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solubilized elastin was purified using Amicon Ultra-0.5 Centrifugal Filters with Ultracel-
10 membranes (MWCO 10,000; Millipore, Billerica, MA).  A Fastin assay (Accurate 
Chemical, Westbury, NY) and an enzyme-linked immunosorbent assay (ELISA) were 
used to quantify elastin and desmosine content, respectively. 
2.3.5 Peptide Competition with -Lactose & RGDS   
To elucidate the role integrins play in elastin fiber assembly, studies were 
conducted in which the EBP or integrins were subjected to competitive binding with EM-
19 and EM-23 using lactose or soluble RGDS, respectively. The galactosugar -
lactose also binds the EBP [175]. However, once -lactose binds the EBP, it changes the 
structural confirmation of the EBP, causing it to be shed from the cell surface [194]. This 
phenomenon results in less elastin fiber production [195].  Soluble RGDS was used as 
another competitive control for integrin binding with EM-23. With its high affinity for 
various integrins, adding RGDS to SMC cultures and quantifying elastin production with 
or without the elastin mimetic peptides was done to shed more insight on the role 
integrins play in elastogenesis. 
In separate experiments, 30,000 SMCs/cm2 were incubated with elastin mimetic 
peptides as well as 10 mM -lactose or 1 mM RGDS solution (sterile-filtered using 0.2 
μm pore size nylon filters; Pall Life Sciences, Port Washington, NY).   The elastin 
mimetic peptides were again added to cell suspensions during the seeding procedure at 
concentrations of 0.01, 0.1, or 1 µmol/ml, this time also in the presence of either -
lactose or RGDS. After a 48 hour incubation period, cell cultures were washed and the 
elastin and desmosine isolated as previously described. 
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2.3.6 Fastin Assay for Assessment of Elastin Production   
A Fastin assay was used to quantify elastin deposition after sample hydrolysis.  In 
brief, samples and α-elastin standards in oxalic acid were treated with an equal volume of 
elastin precipitation reagent containing trichloroacetic acid and hydrochloric acid (HCl) 
for 10 mins.  Following precipitation of elastin, the mixture was centrifuged at 10,000×g 
for 10 mins and the supernatant was discarded.  The recovered sample was incubated 
with 1.0 ml of Fastin dye reagent, containing 5,10,15,20‐tetraphenyl‐21,23‐porphine 
tetra‐sulfonate (TPPS), for 90 mins.  TPPS has an affinity for the basic amino acid side 
chains of elastin.  The elastin-dye complex was then separated via centrifugation at 
10,000×g for 10 mins.  The supernatant was again discarded, and the dye-elastin complex 
was dissociated by adding 250 µl of dye dissociation reagent, containing guanidine HCl 
and propan‐1‐ol.  The final dye extract was placed in a 96-well plate and absorbance was 
read using a Beckman DTX 880 Multimode Plate Reader (Beckman Coulter, Brea, CA) 
at 513 nm. Concentrations of elastin were calculated by comparison with α-elastin 
standards. 
2.3.7 Desmosine ELISA   
A competitive ELISA was used to quantify desmosine content. First, an 
ovalbumin-desmosine conjugate (a gift from Dr. Barry Starcher of the University of 
Texas Health Science Center at Tyler) in 50 mM sodium bicarbonate buffer (pH 8.5) was 
adsorbed to the wells of a 96-well plate for 1 hour at room temperature.  After 1 hour, the 
wells were washed three times with washing buffer composed of 10 mM PBS with 0.05% 
Tween 20.   The wells were blocked by adding 1% bovine serum albumin (BSA; Sigma, 
St. Louis, MO) in 10mM PBS for 30 mins at room temperature, then washed three times 
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with washing buffer.  A primary desmosine antibody (Elastin Products Company, EPC, 
Owensville, MO) in 1% BSA solution (1:1000 dilution) along with either samples or 
standards was added and allowed to interact for 1 hour at room temperature.  After 
primary antibody interaction, the wells were washed three times with washing buffer.  A 
secondary ant-rabbit IgG conjugated with horseradish peroxidase (1:3500 dilution; 
Promega, Madison, WI) was then added to each well and incubated for 1 hour at room 
temperature.  The wells were again washed three times and incubated with o-
phenylenediamine (OPD; Sigma, St. Louis, MO) for 30 mins at room temperature in the 
dark.  The final reaction was quenched by adding 3 M HCl to each well and the 
absorbance of each sample was read using a Beckman DTX 880 Multimode Plate Reader 
at 492 nm. 
2.3.8 Immunofluorescence Staining   
Immunofluorescence staining experiments were conducted to visualize peptide 
colocalization with the elastin matrix. EM-23, EM-23S, EM-19 and EM-19S were each 
conjugated to fluorescein isothiocyanate (FITC). 10 mg of each peptide was dissolved in 
5 ml deionized water, and FITC (1:1 amine mole ratio) was dissolved in 4 ml 0.1 M 
sodium bicarbonate buffer (pH 8.5).  The dye solution was added to the peptide solution 
dropwise and allowed to react for 2 hours.  After 2 hours, any unreacted dye and peptide 
were dialyzed using 2000 MWCO dialysis cassettes (Pierce Biotechnology, Rockford, 
IL) for 2 hours.  The dialyzed product was frozen and lyophilized overnight.  The 
conjugated peptide-dye moiety was dissolved in 10 mM HEPES buffer (pH 7.4) such that 
the final concentration in one 24-well plate would be 1 µmol peptide/ml.  The solution 
was sterilized using 0.2 μm pore size nylon filters (Pall Life Sciences, Port Washington, 
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NY).  The sterile solution was added to each well plate containing 80,000 SMCs/cm2 and 
incubated for 48 hours. 
Immunostaining techniques were then utilized to visualize elastin fibers.  In brief, 
each well was washed with 10 mM PBS, and the cells were fixed with 100% methanol 
for 5 mins.  Wells were again washed with 10 mM PBS and a primary elastin antibody 
(BA-4, Santa Cruz Biotechnology (SCBT), Santa Cruz, CA) at a 1:100 dilution in 10 mM 
PBS was incubated with cell cultures for 2 hours at room temperature.  The wells were 
washed with 10 mM PBS and incubated with a secondary goat anti-mouse IgG 
conjugated with Texas Red (SCBT, Santa Cruz, CA) at a 1:400 dilution for 1 hour at 
room temperature.  Elastin fibers, along with peptide-dye moieties, were visualized 
simultaneously in each well using a Leica DMI 4000B fluorescent microscope (Leica 
Microsystems, Inc.; Bannockburn, IL). 
2.3.9 Quantification of Tropoelastin and LOX mRNA Levels  
Quantitative two-step reverse transcriptase polymerase chain reaction (RT-PCR) 
was conducted after 48 hours of cell culture to elucidate the impact on tropoelastin and 
LOX mRNA levels by soluble EM-19 and EM-23.  Briefly, 1 mol of EM-19 or EM-23 
was first sterile filtered using 0.2 m pore size nylon filters (Pall Life Sciences, New Port 
Washington, KY), mixed with media, and simultaneously seeded with SMCs at a density 
of 30,000 cells/cm2.  Samples without any peptides were used as positive controls. After 
48 hours, the media was aspirated and samples were thoroughly washed with PBS. Cells 
were then detached through incubation with 0.21% trypsin containing 0.25% 
ethylenediaminetetraacetic acid (EDTA; Cellgro, Manassas, VA) at 37°C for 4 mins, and 
resuspended such that each sample contained the same number of cells. Total RNA was 
 29
extracted using the Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA) and RNA 
quality and concentration were determined by taking the ratio of absorbances at 260 and 
280 nm. Complimentary DNA (cDNA) sequences were prepared using the iScript cDNA 
Synthesis Kit (Bio-Rad, Hercules, CA), utilizing a blend of oligo(dT) and random 
hexamer primers.  cDNA was then subjected to PCR amplification using SSoAdvanced 
SYBR Green Supermix (Bio-Rad, Hercules, CA) for tropoelastin, LOX and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which served as an internal 
control, on an Applied Biosystems StepOne Plus instrument (Applied Biosystems, 
Carlsbad, CA). Primers used were (forward) 5’-GCTGACGCTGCTGCAGCCTA-3’ and 
(reverse compliment) 5’-CAGCAAAAGCTCCACCTACA-3’ for tropoelastin and 
(forward) 5’-GCAGATGTCAGAGATTATGATCA-3’ and (reverse compliment) 5’-
ATCGCCTGTGGTAGCCATAGT-3’ for LOX. Amplification included 40 cycles of 
denaturation (95C, 10 s) and annealing/extension (60C, 30 s). Fluorescence generated 
during amplification was used to quantify mRNA levels from SMCs over the different 
conditions. 
2.3.10 Blockage of Integrins  
To investigate the importance of specific integrins in elastic fiber assembly, 
SMCs were first blocked with either anti-vor anti-5 antibodies and elastin content 
was quantified after 48 hours in presence or absence of the elastin mimetic peptides   
Cells were first allowed to adhere in the wells of a 24-well TCPS plate at a cell density of 
30,000 SMCs/cm2 for 4 hours after which the media was removed and replenished with 
media doped with either anti-v1:1000 dilution, Abcam, Cambridge, MA) or anti-
5 (1:1000 dilution, Abcam, Cambridge, MA).  Previous work has confirmed that the 
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integrin 5interacts with the fibronectin derived sequence RGD, as does v[Charo 
1990] Additionally, Bax et al. have shown that the C-terminus of tropoelastin does not 
interact with 5and hence this integrin was used as an appropriate comparison to 
demonstrate the importance of interactions between RGDS and vin the mechanism of 
elastin maturation [155]. Antibodies were incubated with cell cultures for 2 hours, after 
which the media was removed, wells were washed with 10 mM PBS, and replenished 
with fresh media.  EM-23 and EM-19 (1 mol/ml in 10 mM HEPES buffer; pH 7.4) were 
sterile filtered using 0.2 m pore size nylon filters (Pall Life Sciences, New Port 
Washington, KY), added to the media, and incubated with cells for 48 hours. The media 
was then removed, the wells rinsed with PBS, and the well plates were frozen and 
lyophilized.  The contents of each well were hydrolyzed by adding 0.1 N NaOH for 1 
hour at 100°C.  The resulting lysate was centrifuged at 8,000×g for 10 mins and the 
supernatant containing the cell debris and soluble matrix components was removed.  The 
remaining insoluble elastin was resuspended in 0.25 N oxalic acid and further hydrolyzed 
for 48 hours at 100°C.  Following the oxalic acid treatment, the solubilized elastin was 
purified using Amicon Ultra-0.5 Centrifugal Filters with Ultracel-10 membranes 
(MWCO 10,000; Millipore, Billerica, MA).  A Fastin assay (Accurate Chemical, 
Westbury, NY) and an ELISA were used to quantify elastin and desmosine, respectively.  
Well plates treated only with antibodies served as controls.  Separate experiments were 
conducted to quantify elastin production on TCPS surfaces after 48 hours without any 
addition of antibodies or media exchange.  The data showed that elastin production from 
this sample set was comparable to elastin production on TCPS surfaces with media 
exchanged after 4 hours, indicative of minimal cell loss during the media exchange and 
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no significant changes in cell viability in the presence of the antibodies used in these 
studies. An isotype control (mouse monoclonal IgG1, Abcam, Cambridge, MA), which 
was produced against a synthetic hapten not normally present in humans or animals, was 
also tested in the antibody experiments.  
2.3.11 Statistical Analysis 
All experiments were performed minimally in triplicate.  Error bars indicate 
standard deviation, and statistical analysis was performed using a single factor ANOVA; 
p-values < 0.05 were considered to be significant. 
 
2.4 Results 
2.4.1 Circular Dichroism Studies 
 CD studies were conducted on EM-19 and EM-23 to characterize the inherent 
structure and peptide folding in solution (Figure 2.1). Both CD spectra for EM-19 and 
EM-23 at room temperature and 37ºC show a large negative band at 197 nm, indicating a 
disordered structure like the random coil of native human elastin. The addition of the 
RGDS domain in EM-23 decreases the intensity of the negative peak, and, at 
physiological temperature, small yet significant changes were observed between each 
spectra, indicating a structural transformation with respect to temperature. The CD 
spectra show that each peptide has the disordered orientation found in soluble elastin and 
that the peptides behave as elastin mimetics in solution. Furthermore, the CD spectrum of 
soluble human -elastin includes a shoulder at 220 nm, which may be indicative of -
helical structures and are typical features of noncoacervated solutions of soluble elastin. 
However, this shoulder was absent from the CD spectra of EM-19 and EM-23. 
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Figure 2.1. CD Spectra of EM-19 and EM-23, showing a significant amount of disorder as indicated by the 
larger negative peak at 190 nm, which is characteristic of random coil structure of human elastin. The inset 
figure depicts the CD spectra for soluble human -elastin [196]. 
 
2.4.2 Peptide Influence on Elastin and Desmosine Production 
 
 Elastin and desmosine content were quantified in the presence of the elastin 
mimetic peptides, and their respective controls, by a Fastin assay and a competitive 
ELISA after 48 hours (Figure 2.2). In the presence of EM-19, elastin production was 
reduced to 33 ± 12%, 32 ± 8%, and 41 ± 6% of the TCPS control at 0.01, 0.1, and 1 
mol, respectively (Figure 2.2A). This result suggests that the peptide competes with 
tropoelastin to bind the EBP. The shorter peptide sequences replace the heavier 
tropoelastin segments in the maturing elastin fibers, leading to a reduced mass in elastin 
detected. A similar phenomenon was observed with EM-19S; elastin production was 
reduced to 41 ± 7%, 27 ± 10%, and 35 ± 10% of the TCPS control at 0.01, 0.1, and 1 
mol, respectively, even though no binding domains are present in this peptide (Figure 
2.2B). This result is likely due to the lysine-rich domains present in EM-19S that are still 
capable of crosslinking with mature elastin. The desmosine production in the presence of 
either peptide remained unchanged, indicating the crosslinking activity remained 
unchanged (Figure 2.2B). 
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Figure 2.2. Elastin and desmosine content in the presence of EM-19, EM-19S, EM-23, and EM-23S.   
A) EM-19 and EM-19S stimulate decreases in elastin production with increasing peptide concentration.  
Though only EM-19 can bind to the EBP, both peptides are capable of being crosslinked into the elastin 
matrix, thus the total mass of tropoelastin being crosslinked in decreased. B) Both EM-19 peptides cause 
only small fluctuation in desmosine production, indicating that LOX activity is not significantly changed.  
C) The addition of EM-23 in SMC cultures leads to reduced levels of elastin at lower concentrations, 
followed by recovery at the highest concentration indicating an added effect of the RGDS domain. D) EM-
23 and EM-23S also stimulate only small changes in desmosine production compared to controls (n = 7; *p 
< 0.05 compared to TCPS; **p <0.005 compared to scrambled sequences; the data taken for elastin 
deposition for EM-23 at 0.01 mol and 1mol are not significantly different, whereas both conditions are 
significantly different from 0.1 mol with p < 0.02 ). 
 
A similar trend is observed with EM-23; elastin production is reduced to 52 ± 
11% and 39 ± 8% of the control at 0.01 mol and 0.1 mol, respectively (Figure 2.2C). 
However, at 1 mol, elastin deposition is reduced only to 53 ± 12% of the TCPS control 
and recovers to the same amount of the lowest EM-23 concentration. This data suggests 
that, at higher EM-23 concentrations, the peptide preferentially binds integrins over the 
EBP and the higher amount of elastin detected is likely due to EM-23 chaperoned via 
integrins in concert with EBP-bound tropoelastin for crosslinking. The control peptide, 
EM-23S, undergoes a trend similar to that of EM-23, in which elastin deposition is first 


















































































































































respectively, but slightly recovers to 58 ± 21% at 1 mol (Figure 2.2C). This data 
suggests that integrins play a synergistic role with the EBP in elastogenesis. The 
desmosine crosslinking remained unchanged throughout all the concentrations suggesting 
LOX activity was unchanged in the presence of EM-23 or EM-23S (Figure 2.2D). As 
crosslinking controls, desmosine content was quantified after 48 hours in the presence of 
peptides in which lysine was substituted with glycine (EM-19G and EM-23G; Figure 
2.3). The desmosine content remained mostly unchanged throughout all peptide 
concentrations, indicating that LOX activity remained unperturbed.  
  
Figure 2.3. Desmosine production in the presence of EM-19G and EM-23G. No significant changes were 
observed in desmosine production across all peptide concentrations indicating LOX activity was remained 
unchanged (n = 5-6). 
 
 2.4.3 Peptide Competition with -lactose  
Elastin and desmosine content were quantified in the presence of the elastin 
mimetic peptides and 10 mM -lactose after 48 hours (Figure 2.4). The presence of -
lactose alone decreases the elastin content to 120 ± 9% of the TCPS control (Figure 
2.4A). The combination of EM-19 and 10 mM -lactose leads to a competitive behavior 


































increasing peptide concentration (elastin deposition decreased by 103 ± 16%, 46 ± 7%, 
and recovered to 78 ± 21% of the TCPS control at 0.01, 0.1, and 1  mol, respectively,). 
Although the data is normalized to TCPS, it is of note that at the highest EM-19 
concentration, elastin deposition recovers to 5.48 ± 1.81 g, which is only slightly less 
than the 7.23 ± 1.06 g of total elastin production at 1 mol in the absence of -lactose. 
The control peptide, EM-19S, does not have any active binding sites that will interact 
with the EBP, and hence does not compete with -lactose, leading to similar levels of 
elastin production as -lactose across all concentrations (elastin production decreased by 
120 ± 11%, 123 ± 4%, and 126 ± 5% in comparison to the TCPS control at 0.01, 0.1, and 
1 mol, respectively). 
  
Figure 2.4. Elastin and desmosine production as a result of competition between 10 mM -lactose (L) and 
EM-19, EM-19S, EM-23, or EM-23S. A) EM-19 undergoes competition with α-lactose but elastin levels 
show signs of recovery at high concentrations due to competition of the VGVAPG sequence with lactose. 
EM-19S does not compete to bind the EBP and no functional recovery is possible.  B) EM-19 and EM-19S 
stimulate significant increases in desmosine production. C) Elastin levels in the presence of EM-23 and 
EM-23S remain drastically decreased, suggesting the peptide binds to integrins and cannot stimulate EBP 
activity.  D) EM-23 and EM-23S are able to promote desmosine production, yet not at the levels observed 





















































































































































 Desmosine production further decreased to 48 ± 25% of the TCPS control in the 
presence of -lactose alone (Figure 2.4B). Moreover, higher amounts of desmosine in the 
presence of EM-19 and -lactose were detected at the lower concentrations of both EM-
19 sequences (an increase of 44 ± 20% and 15 ± 31% compared to the TCPS control at 
0.01 and 1 mol, respectively), while decreasing to the control levels at 1 mol (98 ± 8% 
of the TCPS control). In the presence of EM-19S and -lactose, however, desmosine 
levels were greater than the TCPS control at all concentrations (an increase of 23 ± 9%, 
12 ± 31%, and 33 ± 23% compared to the control at 0.01, 0.1, and 1  mol, respectively). 
 On the other hand, elastin production did not recover in the presence of EM-23 
and -lactose, reinforcing the possibility that EM-23 preferentially binds to integrins 
instead of the EBP (Figure 2.4C). At each concentration, the elastin levels were 
comparable to the levels observed in the presence of -lactose (reductions of 125% ± 6%, 
226 ± 5%, and 124 ± 9% compared to the TCPS control at 0.01, 0.1, and 1 mol, 
respectively). A similar trend in elastin deposition was also observed in the presence of 
EM-23S and -lactose (reductions of 128 ± 15%, 12% ± 8%, and 128 ± 7% compared to 
the TCPS control at 0.01, 0.1, and 1 mol). The desmosine content, on the other hand, 
increased with increasing EM-23 concentration, although no statistical significance was 
found between the control and peptide concentrations of 0.1 and 1 mol (Figure 2.4D). 
Desmosine content was 73 ± 10% and 94 ± 23% of the TCPS control at 0.01 and 1 mol, 
respectively, whereas it increased by 11 ± 15% at a concentration of 0.1 mol in 
comparison to the control. In the presence of EM-23S, the desmosine content was 53 ± 
12%, 75 ± 28%, and 52 ± 34% compared to the TCPS control at 0.01, 0.1, and 1 mol, 
respectively. 
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2.4.4 Peptide Competition with Soluble RGDS 
 To further characterize the role integrins play in elastin fiber assembly, the 
elastin and desmosine content were quantified after 48 hours in the presence of the elastin 
mimetic peptides and soluble RGDS (Figure 2.5). The addition of RGDS alone decreased 
the elastin levels to 71 ± 30% of the TCPS control (Figure 2.5A). The presence of EM-19 
and RGDS caused a decrease in elastin levels across all concentrations (52 ± 19%, 46 ± 
8%, and 41 ± 21% compared to the TCPS control at 0.01, 0.1, and 1 mol, respectively; 
Figure 2.5A). Desmosine production, on the other hand, remained unchanged throughout 
the entire spectrum of EM-19 concentrations, indicating that LOX activity also remained 
unchanged (Figure 2.5B). 
 
Figure 2.5. Elastin and desmosine production stimulated by EM-19 and EM-23 in the presence of 1 mol 
RGDS.  A) The addition of RGDS alone decreases elastin production in SMC culture, and EM-19 promotes 
further decreases in elastin levels, suggesting that RGDS plays an important role in elastin production.  B) 
Desmosine production decreases with increasing peptide concentration, a trend similar to that observed in 
the presence of lactose. C) EM-23 stimulates a similar trend in elastin content as cultures that did not 
contain RGDS.  The data suggests that there is a synergistic interplay between RGDS and VGVAPG on 
EM-23 that is influencing elastin production.  D) Desmosine production from EM-23 only increases 














































































































































In contrast, elastin production initially decreased at lower EM-23 concentrations 
and eventually recovered at 1 mol (53 ± 10%, 41 ± 27%, and 73 ± 9% compared to the 
TCPS control at 0.01, 0.1, and 1 mol, respectively; Figure 2.5C). The desmosine levels 
remained unchanged across all EM-23 concentrations, indicating LOX activity was 
unchanged (Figure 2.5D). 
2.4.5 Visualizing Peptide Activity via Immunofluorescence 
The bioactivity of the elastin mimetic peptides at 1 mol was visualized using 
immunofluorescence techniques (Figure 2.6). Each peptide was tagged with FITC and the 
elastin fibers were labeled with Texas Red. Strong colocalization of EM-19 and EM-19S 
was observed around the periphery of the cell membrane (Figure 2.6A and 2.6B, 
respectively). However, EM-23 and EM-23S showed an even stronger ability to 
colocalize with the deposited elastin matrix (Figure 2.6C and 2.6D, respectively). 
 
Figure 2.6. Immunofluorescent images of peptide activity in vitro after 24 hours.  Arrows indicate sites of 
peptide localization with the elastin matrix. EM-19 colocalizes strongly with the elastin matrix (A) whereas 
with EM-19S there is less peptide incorporated into the matrix due to the scrambling of the EBP-binding 
sequence (B).  Both EM-23 (C) and EM-23S (D) are able to bind the cell surface and greater colocalization 
is observed compared to the EM-19 peptides. 
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2.4.6 Tropoelastin and LOX mRNA Levels  
 Tropoelastin and LOX mRNA levels were quantified in the presence of the elastin 
mimetic peptides after 48 hours (Figure 2.7). As an internal control, GAPDH mRNA 
levels were also quantified in the presence of the elastin mimetic peptides and their 
respective controls. In the presence of EM-19, tropoelastin mRNA level increased by 7 ± 
2% from the TCPS control samples, and LOX mRNA level decreased by 3 ± 6% from 
the control, however, neither condition was statistically different from the TCPS controls 
(Figures 2.7A and 2.7B, respectively). Moreover, in the presence of EM-19S tropoelastin 
mRNA levels decreased by 3 ± 4% while the LOX mRNA production increased by 10 ± 
5% without any statistical difference from TCPS (Figures 2.7A and 2.7B, respectively). 
Similarly, in the presence of EM-23, tropoelastin and LOX mRNA levels decreased by 
12 ± 6% and 11 ± 15%, respectively, with no statistically significant difference from the 
TCPS control (Figures 2.7A and 2.7B, respectively).  
Furthermore, in the presence of EM-23S, tropoelastin production increased by 22 
± 13% while LOX production decreased by 13 ± 19% without any significant difference 
from TCPS (Figures 2.7A and 2.7B, respectively). Additional statistical analysis between 
samples incubated with EM-19 and EM-23 was also conducted, and no significant 
differences in any mRNA levels were observed between the different samples.  Further, 
no significant changes in GAPDH mRNA levels were observed between the controls and 
samples incubated with either EM-19 or EM-23 (GAPDH mRNA levels decreased by 11 
± 2% when in the presence of EM-19 whereas GAPDH mRNA levels increased by 3 ± 
11% in the presence of EM-23, Figure 2.7C).  No significance in GAPDH mRNA levels 
were also observed between TCPS and EM-19S or EM-23S (GAPDH mRNA levels 
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increased by 8 ± 11% when exposed to EM-19S whereas GAPDH mRNA levels 
increased by 5 ± 12% when exposed to EM-23S, Figure 2.7C). 
 
Figure 2.7. Tropoelastin (A), LOX (B), and GAPDH (C) mRNA levels in the presence of 1 mol of the 
elastin mimetic peptides. No statistical significance in the tropoelastin, LOX, or GAPDH mRNA levels was 
found between the elastin mimetic peptides and TCPS (n = 3-4). 
 
2.4.7 The Role of Integrins in Elastin Fiber Assembly 
 To further assess the roles integrins play in elastin fiber assembly, the elastin and 
desmosine content were quantified after 48 hours in the presence of 1 mol EM-19 or 
EM-23 while the integrins v or 5 were blocked (Figure 2.8). In the presence of the 
vantibody, elastin production reduces to 68 ± 10% of the TCPS control, whereas no 
change in elastin deposition was observed in the presence of the5 antibody (Figure 
2.8A). Moreover, in the presence of EM-19, elastin production reduces to 48 ± 3% and 





































































































presence of EM-23, elastin production reduces to 82 ± 7% and increases by 28 ± 8% 
when vand5 are blocked, respectively (Figure 2.8A). 
 
Figure 2.8. A) Changes in elastin production are evident in the presence of EM-19 and EM-23 when the 
activities of two different integrins, vand5, are blocked.  When the activity of v is blocked, 
elastin production decreases significantly, while no change in elastin activity is observed when the activity 
of 5 is blocked, alluding to the importance of v in elastin fiber assembly.  EM-19 is still capable of 
self-assembling with the elastin matrix in the presence of either antibody, suggesting that the binding 
affinity of EM-19 to the EBP is not affected.  However, blocking the activity of v significantly reduces 
the ability of EM-23 to bind to integrins and as a result, elastin levels are still significantly lowered since 
the peptide is utilizing the EBP.  On the other hand, by blocking the activity of 5 vintegrin-bound 
EM-23 is crosslinked within the elastin matrix in addition to EBP-bound tropoelastin, leading to 
significantly higher elastin production than in control cultures (n = 3-4; *p < 0.05 compared to TCPS).  B)    
Desmosine production in the presence of EM-19 and EM-23 mirrors the elastin levels when vand5 
are blocked.  (n = 4-6, *p < 0.05 compared to TCPS). 
 
 The desmosine data mirrors that of elastin, in that desmosine production reduces 
to 91 ± 4% of the TCPS control when vis blocked (Figure 2.8B). However, no change 
in desmosine production is observed when 5 is blocked. Similarly, in the presence of 
EM-19, no change in desmosine is observed when either vor5 is blocked. 
Although desmosine levels are comparable to TCPS controls in the presence of EM-23 
and the vantibody, a significant increase of 7 ± 4% is observed in the presence of 
EM-23 and the 5 antibody (Figure 2.8B).   
Furthermore, elastin and desmosine production were also quantified in the 
presence of an isotype control and EM-19 or EM-23 (Figure 2.9). The isotype control 
















































































anti‐v antibody  anti‐5 antibody  anti‐v antibody  anti‐5 antibody 
 42
therefore does not react with any antigen of human or animal cells. The addition of the 
isotype control did not affect the overall elastin production, indicating that the antibody 
did not have any cross reactivity with the SMCs (Figure 2.9A). Furthermore, in the 
presence of either EM-19 or EM-23 and the isotype control, the elastin levels remained 
comparable to the levels observed in Figure 2.2 (elastin production reduced to 61 ± 7% 
and 57 ± 8% in comparison to TCPS in the presence of EM-19 and EM-23, respectively). 
The desmosine production remained unchanged throughout all conditions (Figure 2.9B). 
 
 
Figure 2.9. Elastin (A) and desmosine (B) in the presence of IgG isotype control (I) and EM-19 or EM-23. 
Elastin production in the presence of the isotype control and EM-19 or EM-23 is comparable to levels 
observed without the addition of the isotype control, indicating that the antibody does not have any cross 
reactivity with the SMCs. Desmosine production remained unchanged in the presence of the isotype control 




 The ECM is an essential part of any tissue, as it provides the necessary 
microenvironment for cell growth. Currently available biomaterials for vascular 
prostheses lack a viable ECM, and hence are not able create a suitable microenvironment 
for cell growth. For example, elastin is a critical component of vascular ECM yet many 
vascular prostheses lack the ability to promote elastin production [16]. Although the 




































































dominant role in chaperoning tropoelastin during elastogenesis [178]. Moreover, recent 
studies have suggested that integrins may assist the EBP in chaperoning tropoelastin for 
elastogenesis [155-157].  
With this mechanism in mind, two different elastin mimetic peptides, EM-19 and 
EM-23, were engineered to translate the complex mechanism of elastin fiber assembly to 
a synthetic scaffold. Before the peptides could be implemented as templates that promote 
ECM deposition, they first were thoroughly characterized in vitro and their ability to self-
assemble with the growing elastin matrix was evaluated. Further, the role that integrins 
play in the elastogenesis was also investigated. 
 As part of the initial peptide characterization, the native structure of each peptide 
was determined via CD.  No significant differences in the CD spectra for EM-19 and 
EM-23 were found between room temperature and 37ºC. Moreover, the lack of negative 
peaks from 208 to 220 nm in the CD spectra for either peptide suggests the absence of an 
-helical structure. The CD spectra for EM-19 and EM-23 also have a characteristic 
negative band at 197 nm representing a disordered structure such as the random coil of 
human elastin [196]. Also, the spectra are directly comparable to that of soluble human 
elastin suggesting that the peptides are capable of behaving as soluble elastin mimetics 
[197-202].  
 Further, elastin and desmosine production were quantified in the presence of the 
elastin mimetic peptides and their respective controls after 48 hours. The addition of EM-
19 reduced the elastin content by almost 50%. A possible explanation for this 
phenomenon is that the peptide is directly able to compete with native tropoelastin to 
bind the EBP. Once the smaller peptide chain binds the EBP, it is chaperoned to the 
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adjacent microfibrils where the cell-secreted enzyme LOX crosslinks the peptide with the 
elastin matrix. This phenomenon leads to a reduced overall mass of elastin detected 
(Figure 2.10).  
 
Figure 2.10. Proposed mechanism for self-assembly of EM-19 within the elastin matrix. EM-19 readily 
competes with tropoelastin for EBP binding. Once bound on the EBP, the peptide is chaperoned to the 
adjacent microfibrils where the cell-secreted enzyme LOX crosslinks the peptide with the elastin matrix, 
leading to a reduced mass of elastin detected. 
 
This hypothesis was further confirmed by quantifying the desmosine content in 
the presence of EM-19 after 48 hours. The desmosine content remained unchanged across 
all EM-19 concentrations, suggesting that the reduced mass of elastin detected in the 
presence of EM-19 may be a result of the peptide being crosslinked within the elastin 
matrix. A similar phenomenon was also observed in the presence of EM-19S. Although 
EM-19S contains no cell binding motifs, it may be possible for the peptide to be 
crosslinked with the elastin matrix due to the active crosslinking domains, and hence a 
reduced mass of elastin was detected while having no significant impact on desmosine 
production. 
A similar trend in elastin production was observed in the presence of EM-23; 
however, the amount of elastin detected significantly recovered at the highest EM-23 
concentration. A possible explanation for the recovery of elastin levels is a result of the 
peptide preferentially binding integrins instead of the EBP. The integrins and the EBP 
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amounts of elastin detected (Figure 2.11). Furthermore, the desmosine content remained 
the same throughout all EM-23 concentrations, which reinforces the hypothesis that 
peptide crosslinking occurs through a synergistic mechanism between the EBP and 
integrins. Similarly, in the presence of the control sequence, EM-23S, which contains the 
active integrin binding domain, elastin fiber assembly begins to recover at the highest 
concentration, and the desmosine content remains unchanged throughout all EM-23S 
concentrations. This data further strengthens the initial hypothesis of integrins playing an 
integral role in elastogenesis. 
 
 
Figure 2.11. Proposed mechanism of EM-23 crosslinking with the elastin matrix. At low 
concentrations, EM-23 competes with and replaces the heavier tropoelastin chain in crosslinking with the 
elastin matrix leading to a reduced mass of elastin detected (A). However, at the highest concentration, the 
peptide preferentially binds with integrins which play a synergistic role with the EBP to chaperone the 
peptide for crosslinking. The final mass of elastin detected is a result of the heavier tropoelastin chains 
crosslinking with EM-23. 
 
 Further control studies were conducted in which the lysine-rich domain in EM-19 
and EM-23 was replaced with glycine, yielding EM-19G and EM-23G, respectively, and 
the desmosine content was quantified in the presence of EM-19G or EM-23G. No change 
in desmosine content was detected, which suggests that when EM-19G binds to the EBP, 
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absence of crosslinking motifs in EM-19G, the peptide is unable to crosslink with the 
deposited elastin matrix. The EBP is then recycled back to the SMC surface where it 
continues to chaperone the heavier tropoelastin chains for crosslinking. Hence, the 
overall desmosine production remains the same. A similar behavior is also observed with 
EM-23G, even though the peptide preferentially binds integrins at the higher 
concentration. The lack of active crosslinking motifs on EM-23G simply allows 
tropoelastin to crosslink with the elastin matrix, leading to a sustained amount of 
desmosine content detected at each EM-23G concentration. 
 Also, to ensure that the peptides do not have any effects on LOX and tropoelastin 
production, the mRNA levels of LOX and tropoelastin were quantified in the presence of 
EM-19 and EM-23 along with their respective controls. The tropoelastin and LOX 
mRNA levels remained consistent with the TCPS control, indicating that the presence of 
elastin mimetic peptides and their respective controls do not interfere with tropoelastin 
production and LOX activity. The mRNA levels of an internal control, GAPDH, were 
also quantified in the presence of the peptides and as expected no changes were observed 
in the GAPDH mRNA levels. 
The preliminary characterization of EM-19 and EM-23 suggested that the 
peptides can self-assemble with the elastin matrix. However, the role peptides and 
integrins play in elastogenesis remained unclear. Therefore, competitive studies were 
conducted in the presence of -lactose and soluble RGDS to further assess the roles the 
peptides and integrins play in elastogenesis. The galactosugar -lactose has high affinity 
for the EBP. However, when -lactose binds the EBP, the structural conformation of the 
EBP changes and it is shed from the cell surface. This results in a drastic reduction of 
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elastin deposition, since the EBP is unable to transport tropoelastin for elastin 
crosslinking (Figure 2.12).  
Figure 2.12. The binding of the galactosugar -lactose causes a structural transformation of the EBP. The 
EBP is then sheds from the cell surface, leading to a drastic reduction in elastogenesis. 
 
The levels of elastin detected in SMC cultures with -lactose were consistent with 
the mechanism described in Figure 2.12. In the presence of EM-19 and -lactose, elastin 
production almost decreases to the levels observed with only -lactose at 0.01 mol. 
However, elastin production begins to recover as the peptide concentration increases. 
This result suggests that EM-19 may be competing with -lactose for EBP binding, and 
at the highest peptide concentration, EM-19 is able to efficiently bind to the EBP, causing 
peptide incorporation into the elastin matrix. Of note, the actual amount of elastin 
detected was slightly less than the total elastin production at 1 mol in the absence of -
lactose. This remarkable consistency once again reinforces the hypothesis that EM-19 is 
able to effectively compete with -lactose to bind the EBP. On the other hand, EM-19S, 
which does not have an EBP binding motif, did not induce any elastin recovery for any of 
the peptide concentrations. Desmosine content in the presence of EM-19 or EM-19S and 
-lactose varied greatly, showing that the peptides are still able to crosslink due to the 
lysine rich domains present within the peptides. 
 On the other hand, elastin production did not recover at the any of the 
concentrations when SMCs were cultured in the presence of EM-23 and -lactose. This 
result suggests that EM-23 does not compete with -lactose and instead preferentially 
binds to integrins. A similar behavior is also observed with EM-23S, although this result 
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is to be expected due to the absence of the EBP-binding motif. Desmosine production 
once again varied greatly with each EM-23 or EM-23S concentration, suggesting that the 
crosslinking activities are greatly affected when the EBP is completely shed from the cell 
surface. Overall, the competition studies with -lactose suggested that EM-23 
preferentially binds to the cell surface integrins instead of the EBP.  
To elucidate how the binding of EM-23 and integrins affects elastin production, 
further competitive studies were conducted in the presence of soluble RGDS and EM-19 
or EM-23. Elastin and desmosine content were quantified in the presence of soluble 
RGDS and the elastin mimetic peptides. The addition of RGDS alone decreases the 
elastin production by 30%, with EM-19 further reducing the amounts of elastin detected, 
suggesting that by blocking integrin activity, the mechanism of elastin production is 
somehow inhibited. Desmosine production decreases in the presence of RGDS and 
increasing EM-19 concentrations, a trend similar to that found in presence of -lactose. 
Moreover, EM-23 is able to effectively compete with RGDS for integrin binding and is 
able to maintain similar levels of elastin and desmosine as in cultures without any 
addition of RGDS. 
 Integrins are a broad class of receptors and of the 24 different heterodimers of the 
integrin family, previous work has shown tropoelastin to interacts with v[155, 203].  
Therefore to clarify the role v plays in elastogenesis, total elastin content after 48 
hours was quantified in the presence of either EM-19 or EM-23 while blocking the 
activities of vPrevious work has also suggested that the integrin 5does not 
interact with tropoelastin, though it does bind RGDS, and hence this integrin was used as 
a control [155, 204]. When the activity of vwas blocked, elastin production decreased 
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by almost 40%, while no change in elastin deposition was observed when the activity of 
5 was blocked. This result further reinforces that 5 does not play a role in elastin 
fiber assembly, whereas hindering the ability of tropoelastin to interact with vreduces 
elastin deposition and reaffirms the importance of v in elastin fiber assembly. In the 
presence of EM-19 and anti-v or anti-5, elastin production decreases to the levels 
observed in SMC cultures without the antibodies, suggesting that EM-19 is still able to 
effectively bind to the EBP. Once bound to the EBP, the peptide is still able to self-
assemble with the deposited elastin matrix. No change in desmosine production was 
observed in the presence of EM-19 and either anti-v or anti-5, suggesting that 
LOX activity was unperturbed and the peptide was able to self-assemble with the elastin 
matrix. 
 On the other hand, EM-23 contains VGVAPG and RGDS sequences that bind to 
the EBP and integrins, respectively. In the presence of anti-v, elastin production 
decreased by 25%. This result is in excellent agreement with the competitive experiment 
with soluble RGDS, in which elastin production was reduced by 30% in the presence of 
EM-23 and RGDS. Both sets of data suggest that blocking the activity of integrin v 
will inhibit tropoelastin binding to v hindering elastogenesis. In the presence of EM-
23 and anti-5, elastin production increased by 20%. As suggested previously with 
competition studies in the presence of -lactose, EM-23 preferentially binds integrins 
with higher affinity than the EBP. By blocking the activity of 5, the interactions 
between EM-23 and v were enhanced. This allowed both the peptide and tropoelastin 
bound to the EBP to simultaneously crosslink, leading to an increased mass of elastin 
detected. 
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 Desmosine production mirrored that of elastin production; no change in 
desmosine content was detected in the presence of EM-23 and anti-v. A significant 
increase in desmosine production was observed in the presence of EM-23 and anti-5, 
suggesting that the increased crosslinks are a result of both the peptide and tropoelastin 
incorporation into elastic fibers. Elastin and desmosine production were also quantified in 
the presence of EM-19 or EM-23 and an isotype control that does not have any cross-
reactivity with human SMCs. As expected, elastin and desmosine levels were similar to 
those observed in SMC cultures without the presence of the isotype control. 
 Finally, the self-assembly of each elastin mimetic peptide with elastin was also 
visually evaluated. Each elastin mimetic peptide was conjugated with FITC (green 
fluorescence) and incubated with SMCs for 48 hours. The deposited elastin matrix was 
then tagged with Texas Red (red fluorescence) using immunostaining techniques and 
both tagged moieties were visualized under a fluorescence microscope. EM-19 
colocalized well around the periphery of the cell membrane and some colocalization of 
EM-19S was also observed. This is likely due to the presence of the active crosslinking 
domains allowing the peptide to self-assemble with the elastin matrix. Qualitatively, 
stronger localization was observed in the presence of EM-23, which reinforces the initial 
hypothesis that EM-23 can utilize the two different receptors to self-assemble with the 
elastin matrix. Although EM-23S colocalizes fairly well around the cell membrane, the 






 Preliminary characterization studies showed that both engineered peptides were 
able to self-assemble with a cell secreted elastin matrix. Moreover, the role integrins play 
in elastogenesis was also investigated and the results suggested that EM-23 preferentially 
binds with integrins, and the integrin v may play a synergistic role with the EBP in 
elastogenesis. The studies confirmed that the peptides are capable of utilizing the EBP 
and integrins to self-assemble with a growing elastin matrix.  Furthermore, incorporation 
of these peptides into synthetic scaffolds will serve as templates for promoting elastin 
production. As such, the next chapter will discuss the efficacy of EM-19 and EM-23 to 
serve as templates for translating the complex mechanism of elastin fiber assembly once 




Synthesis and Characterization of PEG-peptide Copolymer Hydrogels 
 
3.1 Summary 
 This chapter will characterize the ability of each elastin mimetic peptide to 
facilitate cell adhesion and elastin deposition on the surfaces of PEG-DA hydrogels. Each 
elastin mimetic peptide was physically immobilized onto hydrogel surfaces and SMC 
adhesion, proliferation, and viability studies were conducted at various PEG-peptide 
concentrations. Elastin production was also quantified and compared to cells cultured on 
a TCPS surface. The results from 2D characterization studies suggested that EM-23 
facilities the highest amounts of cell adhesion, spreading, viability, and elastin production 
over all peptides, including RGDS. 
 
3.2 Introduction 
 Immobilizing peptides onto PEG-DA hydrogel surfaces has previously been 
shown to be a suitable model system for characterizing the efficacy of peptides to 
promote cell adhesion, proliferation, and ECM deposition on a synthetic construct [82, 
85, 205, 206]. Moreover, Hern et al. have shown significant cell adhesion on PEG-DA 
surfaces modified with the fibronectin-derived sequence RGDS [191]. Additionally, 
                                                 
 
 
2 Work discussed in this chapter is adapted from: 
D Patel, SE Vandromme, ME Reid, LJ Taite. “Synergistic activity of v3 integrins and the elastin binding 




Gobin et al. immobilized the elastin-derived sequence VAPG onto the surface of PEG-
DA and observed significant cell adhesion [86].  
Furthermore, PEG-DA hydrogels limit non-specific protein adsorption, reduce 
platelet aggregation and thrombosis, and their mechanical properties can be changed by 
simply changing the molecular weight of the polymer [81-85, 89, 207]. The hydrogels are 
fabricated under mild conditions in the presence of a photoinitiator, such as 2, 2 
dimethyl-2-phenyl-acetophenone (DMAP), and UV light at a wavelength of 365 nm 
(Figure 3.1) [208]. In this work, PEG-DA hydrogel surfaces were modified with different 
concentrations of RGDS, EM-19, and EM-23 in order to assess SMC adhesion, 
spreading, viability, and elastin deposition. Moreover, the 2D surface studies evaluated 
the efficacy of the peptides to promote ECM deposition onto a synthetic construct and 
characterized the peptides for potential application towards engineering viable vascular 
grafts. 
 
Figure 3.1. PEG-DA hydrogel formation. In the presence of UV light and a photoinitiator, the acrylate 
groups form free radicals and crosslink to generate a swollen hydrogel matrix. The mesh size of the 
hydrogel is determined by the length of the PEG chain. 
 
  
3.3 Materials and Methods 
3.3.1 Peptide Synthesis  
All materials and reagents required for peptide synthesis were purchased from 








peptide synthesis protocols, as previously described [87].  In brief, four different peptides 
were synthesized using standard HBTU coupling and Fmoc protection chemistry on an 
Apex 396 peptide synthesizer (AAPPTec; Louisville, KY) using a lysine-conjugated 
Wang resin. A 23 amino acid sequence (EM-23; 
AAKAAKVGVAPGRGDSAAKAAKK), containing two cell adhesion motifs 
(VGVAPG and RGDS) as well as lysine and alanine -rich crosslinking domains, was 
synthesized along with a 23 amino acid control peptide in which the VGVAPG sequence 
is scrambled and the RGDS sequence is left intact (EM-23S; 
AAKAAKVGVPAGRGDSAAKAAKK).  A 19 amino acid sequence (EM-19; 
AAKAAKVGVAPGAAKAAKK) and a 19 amino acid peptide in which the VGVAPG 
sequence is scrambled (EM-19S; AAKAAKVGVPAGAAKAAKK) were synthesized, 
omitting the RGDS motif completely to observe the importance of integrin binding. 
Crude peptides were then cleaved from the resin with cleaving cocktail (95% 
trifluoroacetic acid, 2.5% water, 2.5% triisopropylsilane) and purified by dialysis using 
cellulose ester membrane tubing (MWCO 1000; Spectrum laboratories, Rancho 
Dominguez, CA).  The dialyzed peptides were then frozen and lyophilized overnight.  
Peptides were characterized using mass spectrometry.  
3.3.2 Cell Culture and Maintenance 
 Human aortic smooth muscle cells (SMCs, passages 3-5; Invitrogen Inc., 
Carlsbad, CA), were used for the remainder of the work discussed in this chapter.   SMCs 
were maintained in Medium 231 (Invitrogen Inc., Carlsbad, CA) supplemented with 
smooth muscle cell growth supplement (SMGS, Invitrogen Inc., Carlsbad, CA), 2 mM L-
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glutamine, 1 unit/ml penicillin, and 100 mg/l streptomycin (GPS; Cellgro, Manassas, 
VA) at 37°C in a 5% CO2 environment. 
3.3.3 PEG-DA Synthesis 
Synthesis of PEG-DA was conducted using well established protocols [81, 86, 
209].  PEG-DA was synthesized by dissolving 24 g dry PEG (MW: 10000; Fluka, 
Milwaukee, WI) in 20 ml anhydrous dichloromethane (DCM) with an equimolar amount 
of triethylamine and 0.869 g acryloyl chloride (Lancaster Synthesis, Windham, NH) 
added dropwise.  The mixture was stirred under argon for 24 hours, washed with 2M 
K2CO3, and separated into aqueous and DCM phases to remove HCl.  The mixture was 
then centrifuged at 2,000×g for 1 hour and the aqueous phase was aspirated and 
discarded.  PEG-DA was then precipitated in diethyl ether, filtered, and dried under 
vacuum at room temperature overnight.  The resulting polymer was dialyzed overnight 
against DI water with 5 kDa MWCO cellulose ester tubing (Spectrum Laboratories, 
Rancho Dominguez, CA) to remove any residual salts and impurities. The polymer was 
also characterized via proton NMR. 
3.3.4 Conjugation of Peptides to Monoacrylate PEG Derivative  
Peptide sequences (RGDS, EM-19, EM-19S, EM-23 and EM-23S) were 
conjugated to PEG monoacrylate by reaction with acryloyl- PEG-succinimidyl valerate 
(PEG-SVA, MW 3400; Laysan Bio Inc., Arab, AL) in 50 mM sodium bicarbonate (pH 
8.5) at a 1:1 molar ratio for 2 hours (protected from light and under Argon) to yield a 
PEG-peptide moiety.  The mixture was then dialyzed (3500 MWCO dialysis cassettes; 
Pierce Biotechnology, Rockford, IL) against deionized water for 2 hours, lyophilized, and 
stored at –80C.  The final yield for each peptide-conjugated moiety was 82%. The yield 
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was determined by dividing the moles of the resulting product by the moles of the 
expected product. UV-Vis spectroscopy and GPC equipped with UV and ELS detectors 
(Agilent Technologies, Inc., Santa Clara, CA) were used to determine the coupling 
efficiency.  
The number average molecular weight (Mn), the weight average molecular 
weight (Mw), and the polydispersity index (PDI) were determined by GPC using 
polystyrene standards. GPC results showed the expected molecular weights for all of the 
acrylate-PEG-peptide polymers with low PDIs (Mw ≈ 5700, PDI = 1.02 for acrylate-
PEG-EM23 and acrylate-PEG-EM23S; Mw ≈ 5500, PDI = 1.01 for acrylate-PEG-EM19 
and acrylate-PEG-EM19S). The low PDIs and consistent molecular weights confirm 
successful conjugation of the peptides with acrylate-PEG-SVA at the expected molar 
ratios. 
3.3.5 PEG-peptide Grafting Efficiencies  
The grafting efficiencies of the monoacrylate PEG-peptide on the PEG-DA 
surfaces were quantified using the Ninhydrin reagent, which detects amine residues on 
proteins or peptides [70, 84, 210].  PEG-DA was dissolved in 10 mM HEPES buffer (pH 
7.4) at 0.1 g/mL and to this solution, 10 L/mL of the photoinitiator DMAP (Alfa Aesar, 
Ward Hill, MA) in N-vinylpyrrolidone (NVP; 300 mg/mL) was added.  This precursor 
solution was injected between two glass slides separated by a 1.0 mm spacer (C.B.S. 
Scientific Company, Del Mar, CA) and exposed to UV light (365 nm, 10 mW/cm2) to 
form a thin, flat hydrogel.  The top glass slide was then lifted and the hydrogel was rinsed 
with PBS.  A 2 mL solution of PEG-peptide, at 5 mol/ml, containing 10 L/mL DMAP 
was used to coat the surface and the top glass slide was carefully replaced to distribute 
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the PEG-peptide solution evenly on the surface.  The mold was then exposed to UV light 
and the monoacrylate PEG peptide was allowed to crosslink to the surface of PEG-DA. 
Previous work has shown that this method allows for efficient crosslinking of a PEG-
peptide to a PEG-DA surface [81, 207].  Residual PEG-peptide solution and DMAP were 
rinsed away with PBS and 14.3 mm diameter samples were cut.  
The samples were then hydrolyzed with 6 N HCl overnight at 100C, after which 
the solubilized gels were neutralized, frozen, and lyophilized. The dried gels were then 
resuspended in 1 ml sodium citrate buffer (pH 5.0) followed by the addition of 1 ml of 
the Ninhydrin reagent (Spectrum Chemicals, New Brunswick, NJ).  The reaction mixture 
was immersed in boiling water for 15 mins, allowed to cool, and sample absorbances 
were read at 570 nm.  A standard curve comprised of known concentrations of soluble 
PEG-peptide were used to determine the concentration of the monoacrylate PEG-peptide 
grafted on the PEG-DA surfaces.  
3.3.6 Cell Adhesion and Proliferation on PEG-peptide Hydrogels  
SMC cell adhesion and growth on PEG-DA surfaces modified with various 
concentrations of RGDS, EM-19, EM-19S, EM-23 or EM-23S was determined after 
culturing cells on hydrogels for 12 hours to assess adhesion or 48 hours to assess 
proliferation. Different PEG-peptide moieties, at varying concentrations, were grafted 
onto PEG-DA surfaces in the manner described above, in a sterile environment. After 
rinsing the residual peptide solution and DMAP from the PEG-DA surface, 14.3 mm 
diameter gel samples were cut and carefully placed into the wells of a 24 well plate.  
After a 2 hour incubation with SMC media, the swollen gels were rinsed with PBS and 
seeded with 30,000 SMCs/cm2 in fresh media. Cell adhesion and proliferation was 
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assessed after 12 and 48 hours, respectively, by first removing the media and rinsing the 
hydrogels with PBS, carefully transferring the rinsed gels to a new 24 well plate, and 
finally detaching the cells through incubation with 0.21% trypsin containing 0.25% 
EDTA (Cellgro, Manassas, VA) at 37°C for 4 mins. The dissociated cells were counted 
using a Beckman Z1 particle counter (Beckman Coulter, Brea, CA).  
3.3.7 Cell Spreading on PEG-peptide Hydrogels  
Cell spreading was also quantified using different concentrations of PEG-peptide 
conjugated to hydrogels.  Briefly, PEG-peptide (EM-19, EM-23, or RGDS) was 
immobilized on the surfaces of PEG-DA hydrogels in the manner described above.  The 
gels were allowed to swell in media for 2 hours and then replenished with fresh media.  
SMCs at 30,000 cells/cm2 were subsequently seeded and allowed to interact with the 
peptide modified gel.  After 48 hours of incubation, the media was removed and the cells 
were fixed with 4% formaldehyde solution (AAT Bioquest, Inc., Sunnyvale, CA) for 25 
mins.  The residual formaldehyde solution was then removed and the gels were rinsed 
thoroughly with PBS.  Images were then collected using a Leica DMI 400B phase 
contrast microscope (Leica Microsystems Inc., Bannockburn, IL) and cell spreading was 
evaluated by quantifying cell area using ImageJ software (NIH Scion Image, version 1.6, 
http://imagej.nih.gov/ij). 
3.3.8 Cell Viability on PEG-peptide Hydrogels  
Cell viability on PEG-peptide modified hydrogels was also assessed using a 
Live/Dead viability stain (Invitrogen Inc., Carlsbad, CA).  In brief, gels with SMCs were 
prepared with different PEG-peptide concentrations in the manner described above.  
After 48 hours, the media was removed and the gels were rinsed thoroughly with PBS. 
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The gels were then incubated with a solution containing 2 M calcein AM and 4 M 
ethidium homodimer-1 for 20 mins at 37°C.  The intracellular enzyme esterase, present in 
live cells, converts the non-fluorescent calcein AM to green fluorescent calcein.  
Ethidium homodimer-1 enters dead cells via ruptured membranes and subsequent binding 
with nucleic acids produces red fluorescence.  The wells were then washed thoroughly 
with PBS and fluorescent images were taken with a Leica DMI 400B fluorescent 
microscope (Leica Microsystems Inc., Bannockburn, IL).  Fluorescence for each 
condition was also quantified using a Beckman DTX 880 Multimode Plate Reader at 495 
nm excitation/523 nm emission and 495 nm excitation/623 nm emission for fluorescent 
calcein and ethidium homodimer-1, respectively. 
 3.3.9 Biochemical Analysis of PEG-peptide hydrogels 
The amount of elastin deposited on hydrogels was also quantified on PEG-DA 
surfaces modified with RGDS, EM-19, and EM-23 at 5 mol.  Briefly, 5 mol/ml of 
PEG-peptide was immobilized on the surface of a PEG-DA hydrogel as described above.  
After swelling in cell culture media for 2 hours, the media was removed, rinsed with 
PBS, and subsequently seeded with 30,000 SMC/cm2 in fresh media.  After 48 hours, the 
media was again removed and the hydrogels were rinsed thoroughly with PBS.  
Immediately after rinsing, the gels were subjected to hydrolysis with 0.1 N NaOH for 24 
hours at 37°C.  The samples were then transferred to a 100°C oven for 2 hours to further 
solubilize ECM matrix proteins other than elastin.  The digested samples were then 
centrifuged at 8,000×g for 10 min; the resultant pellets were subjected to analysis for 
elastin content, while the supernatants were discarded.  
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3.3.10 Hydrogel Elastin Content  
The amount of elastin on PEG-DA hydrogels was determined using the Ninhydrin 
reagent.  Initially, a Fastin assay was used to quantify elastin content from the hydrolyzed 
PEG-DA samples, as done in Chapter 2 of this thesis.  However, the PEG chains 
interfered with the Fastin assay and instead the Ninhydrin reagent was used to quantify 
the purified elastin (previously separated from all the other proteins). The collected 
protein pellets were further subjected to acid hydrolysis using 6 N HCl at 100°C for 24 
hours.  The digested samples were then dried and resuspended in 1 mL sodium citrate 
buffer (0.1 M, pH 5.0).  To this suspension, 1 ml of Ninhydrin reagent (Spectrum 
Chemicals, New Brunswick, NJ) was added.  The reaction mixture was immersed in 
boiling water for 15 mins, allowed to cool, and sample absorbances were read at 570 nm.  
A standard curve comprised of known concentrations of soluble -elastin in sodium 
citrate buffer (0.1 M, pH 5.0) was used to determine the elastin content of each sample.   
3.3.11 Statistical Analysis 
All experiments were performed minimally in triplicate.  Error bars indicate 
standard deviation, and statistical analysis was performed using a single factor ANOVA; 
p-values < 0.05 were considered to be significant. 
 
3.4 Results 
3.4.1 Grafting Efficiencies of Peptides on PEG-DA Surfaces 
 A grafting efficiency of 4.3 ± 0.11% for was achieved PEG-RGDS (Figure 3.2), 
and this result was comparable to the values reported by Hahn et al. [82]. Further, 
grafting efficiencies of 2 ± 0.15% and 1.1 ± 0.07% were achieved for PEG-EM19 and 
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PEG-EM23, respectively. The lower grafting efficiencies of PEG-EM19 and PEG-EM23 




Figure 3.2. Grafting efficiencies of PEG-EM19 and PEG-EM23 in comparison to PEG-RGDS. Grafting 
efficiencies of PEG-EM19 and PEG-EM23 were significantly lower than PEG-RGDS, suggesting that the 
longer peptide chains may be sterically hindered in the immobilization of the peptide onto the PEG-DA 
surface. (n = 3-5; *p<0.05 from PEG-RGDS; **p < 0.05 from PEG-EM19). 
 
3.4.2 Cell Adhesion on PEG-peptide Hydrogels 
SMC adhesion after 12 hours increased to 1280 ± 139%, 632 ± 23%, 7065 ± 
301%, and 1287 ± 134% on PEG-RGDS, PEG-EM19, PEG-EM23, and PEG-EM23S 
modified surfaces at 5 mol in comparison to unmodified PEG-DA hydrogels, 
respectively (Figure 3.3). As expected, no significant differences were observed in cell 































Figure 3.3. SMC adhesion on PEG-peptide surface at 5 mol after 12 hours. All conditions except for EM-
19S were able to significantly increase SMC adhesion over PEG-DA. (n = 3-5; *p < 0.05 compared to 
PEG-DA). 
 
After 48 hours, all PEG-peptide moieties except EM-19S were able to 
significantly increase SMC adhesion compared to PEG-DA hydrogels (Figure 3.4). PEG-
RGDS grafted surfaces increased SMC adhesion to 424 ± 17.7%, 649 ± 52%, 835 ± 
235%, and 437 ± 254% in comparison to PEG-DA hydrogels at 0.01, 0.1, 1, and 5 mol, 
respectively. SMC adhesion on PEG-EM23S modified surfaces were comparable to 
PEG-RGDS at lower concentrations, measuring 484 ± 37% and 492 ± 52% in 
comparison to PEG-DA hydrogels at 0.01 and 0.1 mol, respectively. At the higher PEG-
EM23S concentrations, SMC adhesion increased to 1142 ± 84% and 836 ± 56% in 
comparison to PEG-DA hydrogels at 1 and 5 mol, respectively. SMC adhesion between 
PEG-RGDS and PEG-EM23S was not statistically significant except the highest peptide 
































Figure 3.4. The number of adherent SMCs on PEG hydrogels grafted with RGDS, EM-19, EM-19S, EM-
23, and EM-23S at various concentrations was observed 48 hours after seeding cells.  All PEG-peptide 
moieties were able to significantly increase SMC adhesion at all concentrations when compared to PEG-
DA.  PEG-EM23, which utilizes both the v3 and the EBP binding motifs, had the highest impact on SMC 
adhesion even at lower concentrations (n = 3-5; *p < 0.05 compared to PEG-DA, **p < 0.0002 compared 
to PEG-RGDS). 
 
In the presence of PEG-EM19, SMC adhesion increased to 365 ± 78%, 470 ± 
100%, 540 ± 101%, and 600 ± 93% in comparison to PEG-DA hydrogels at 0.01, 0.1, 1, 
and 5 mol, respectively. PEG-EM19S, on the other hand, did not stimulate any increases 
in SMC adhesion at any concentrations. Remarkably, PEG-EM23 had the most impact on 
SMC adhesion at all concentrations grafted onto the PEG-DA surface. SMC adhesion 
increased to 2600 ± 214%, 2914 ± 352%, 3471 ± 396%, and 6427 ± 235% in comparison 
to PEG-DA hydrogels at 0.01, 0.1, 1, and 5 mol, respectively.  
3.4.3 SMC Spreading on PEG-peptide Surfaces 
 For all three peptides, cell spreading was a function of peptide concentration, and 
SMC spreading increased with increasing PEG-peptide concentration (Figure 3.5). On 
PEG-RGDS modified hydrogel surfaces, SMC spreading increased to 11 ± 2%, 54 ± 8%, 
72 ± 9%, and 99 ± 4% of the TCPS control at 0.01, 0.1, 1, and 5 mol, respectively. On 
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the other hand, PEG-EM19 facilitated SMC spreading to 40 ± 4%, 63 ± 4%, 77 ± 5%, 
and 95 ± 6% of the TCPS control at 0.01, 0.1, 1, and 5 mol, respectively. Similarly, 
PEG-EM23 also facilitated SMC spreading to 42 ± 5%, 74 ± 4%, 85 ± 6%, and 97 ± 5% 
of the TCPS control at 0.01, 0.1, 1, and 5 mol, respectively.  
 
 
Figure 3.5. SMC spreading on PEG hydrogels grafted with RGDS, EM-19, and EM-23 at different 
concentrations was also observed after 48 hours.  PEG-EM19 and PEG-EM23 both had significant impacts 
on cell spreading in comparison to PEG-RGDS at lower concentrations.  In all cases, cell spreading 
increased to the levels of TCPS at the highest PEG-peptide concentration (n = 8; *p < 0.05 compared to 
PEG-RGDS). 
 
3.4.4 Quantifying and Visualizing Cell Viability on PEG-peptide Surfaces  
 
Cell viability was also a function of peptide concentration; increasing the PEG-peptide 
concentration grafted onto the hydrogel surface increased the SMC viability (Figure 
3.6A). For all peptides, the 5 mol condition gave the highest cell viability, with 87.6 ± 
3.6%, 92.1 ± 1.9%, and 94 ± 1.7% of the TCPS values for PEG-RGDS, PEG-EM19, and 
PEG-EM23 respectively. Furthermore, the amounts of cell adhesion, spreading, and 
viability were visually confirmed in Figure 3.6B. EM-23 at 5 mol showed the most 
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significant amounts of SMC adhesion, spreading, and viability compared to the other 
peptides. 
 
Figure 3.6. A) Quantitative assessment of SMC viability on PEG hydrogels grafted with RGDS, EM-19, 
and EM-23 at various concentrations was observed using a fluorescent Live/Dead viability stain.  Cell 
viability increased with increasing PEG-peptide concentration; the highest viability for each PEG-grafted 
peptide was achieved at the 5 mol concentration (n = 4-5; *p < 0.05 compared to PEG-RGDS).  B)  
Fluorescent images of SMC adhesion on different PEG-DA hydrogels grafted with RGDS, EM-19, and 
EM-23 show the extent of cell viability adhesion and spreading.  Green fluorescence is indicative of viable 
cells, whereas red fluorescence is indicative of dead cells.  Cells were fully spread to the levels of the 
control at the highest PEG-peptide concentration with PEG-EM23 showing the greatest amount of SMC 





3.4.5 Quantifying Elastin Deposition over PEG-peptide Surfaces. 
  PEG-RGDS, PEG-EM19, and PEG-EM23S stimulated elastin production to 
approximately 64 ± 12%, 69 ± 10%, 45 ± 11% of the TCPS control, respectively (Figure 
3.7). However, PEG-EM23 was able to promote comparable elastin deposition to TCPS, 
even though TCPS had ~4.5 more cells adhered than PEG-EM23 (elastin production 
increased by 35 ± 28% compared to TCPS). 
  
Figure 3.7.  Elastin content from different PEG-peptides grafted on PEG hydrogels at 5 mol.  PEG-EM23 
had comparable elastin deposition as TCPS suggesting the ability of the peptide to utilize importance the 
two binding motifs for v3 and the EBP in elastin fiber assembly.  PEG-EM19S and PEG-EM23S had 
elastin and desmosine levels comparable to PEG-DA and PEG-RGDS, respectively   (n = 3-4; *p < 0.05 




 The next step in characterizing the elastin mimetic peptides was to physically 
immobilize them onto the surface of a PEG-DA hydrogel and evaluate the efficacy of the 
peptides to promote SMC adhesion, spreading, viability, and elastin deposition on the 
synthetic substrate. In order to immobilize a peptide onto the surface of the hydrogel, the 
peptides were first reacted with a mononacrylate PEG derivative to yield an acrylate-




































the free acrylates present on the surface of the PEG-DA hydrogel, conjugating the peptide 
onto the surface. 
 For the studies discussed in this chapter, PEG-SVA at 3400 g/mol was used as the 
conjugating polymer. The succinimide ester on PEG-SVA is highly reactive and under 
basic conditions (pH 8.5), the ester group reacts with nucleophiles, such as free amines 
on peptides, to form an acylated product (Figure 3.8) [191]. 
 
Figure 3.8. Reaction of PEG-SVA with a peptide bearing a free amine. The succinimide ester on PEG-
SVA undergoes a substitution reaction with a free amine on the peptide giving a monoacylated-PEG-
peptide moiety. 
 
 Reactions with either primary or secondary amines on peptides create stable amide 
linkages that do not readily break down [191, 211]. Previous work has suggested that the 
PEG spacer at 3400 g/mol allows the conjugated peptide on the PEG-peptide moiety to 
move flexibly, permitting cell spreading and adhesion [191, 211]. 
 After PEG-SVA was conjugated to the elastin mimetic peptides, the grafting 
efficiency of different PEG-peptide moieties on the surfaces of PEG-DA hydrogels was 
determined using the Ninhydrin reagent. The amount of PEG-EM19 and PEG-EM23 
grafted onto hydrogels was significantly lower than that of PEG-RGDS. Grafting 
efficiencies of PEG-EM19 and PEG-EM23 were likely lower due to the longer peptide 
chains causing steric hindrance during the grafting procedure. Moreover, each elastin 
mimetic peptide has more than one free amine that could react with PEG-SVA. However, 






ratio and no side reactions occurred during the coupling process (see Appendix, Figures 
A.1 and A.2). 
SMC adhesion was quantified after 12 hours on different PEG-peptide modified 
surfaces at 5 mol over PEG-DA hydrogels. PEG-RGDS served as a positive control. All 
of the peptides except EM-19S were able to significantly increase SMC adhesion over 
PEG-DA hydrogels. EM-23, on the other hand, had the highest impact on SMC adhesion. 
A similar trend in SMC adhesion was also observed after 48 hours; although higher 
amounts of cell adhesion were observed after 12 hours on PEG-RGDS, PEG-EM23, and 
PEG-EM23S grafted surfaces. This result suggests that the peptides may primarily serve 
as cell adhesion motifs, while not promoting cell proliferation. 
As expected, all of the peptides besides PEG-EM19S were able to significantly 
increase SMC adhesion after 48 hours compared to PEG-DA hydrogels. SMC adhesion 
on PEG-EM23S surfaces was comparable to PEG-RGDS, suggesting that the longer 
peptide chains do not interfere with cell adhesion. More importantly, PEG-EM23 had the 
highest impact on SMC adhesion even though the conjugation efficiency was four times 
lower than that of PEG-RGDS and approximately half that of PEG-EM19. This dramatic 
increase in cell adhesion and growth is indicative of a highly synergistic relationship 
between the EBP and vintegrins in facilitating cell adhesion to the PEG-DA hydrogel. 
Bax et al. have shown that the C-terminus of tropoelastin interacts with the vintegrin 
and numerous other studies have also confirmed this phenomenon (Figure 3.9) [122, 130, 
155, 176]. Through EM-19, specific cell adhesion on a PEG-DA surface was tailored via 
the interaction between the EBP and VGVAPG. However, the results suggested that more 
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significant cell adhesion on a hydrogel surface was achieved by utilizing both the RGDS 
and VGVAPG domains to interact with the vintegrin and the EBP, respectively.  
 
 
Figure 3.9. A ) Elastic fiber assembly is a complex mechanism involving intracellular transport of 
tropoelastin to the cell surface receptor known as EBP.  The EBP transports the protein to adjacent 
microfibrils for crosslinking by cell-secreted LOX after which the EBP is recycled to repeat the process.  
Recent discoveries have shown that the C-terminus of tropoelastin interacts with the integrin v3 which 
also plays an important, yet unknown role in elastin fiber assembly [155-158]. B) PEG-DA hydrogels 
tailored with bioactive peptides which utilize the v3 and the EBP binding motifs approximates the 
complex mechanism for elastin fiber assembly occurring in vivo.  This direct translation results in mature 
elastin crosslinked to the PEG matrix from a network of cell secreted tropoelastin and PEG-grafted elastin 
mimetic peptide. 
 
Moreover, increased SMC adhesion was observed on EM-23 grafted surfaces 
compared to previously published results which have shown SMC adhesion to a lesser 
extent on different synthetic substrates.  For example, Mann et al. modified glass surfaces 
with VGVAPG and found a 200% increase in SMC adhesion over unmodified glass 
surfaces [212]. Further, Rashid et al. fabricated vascular grafts from PUs and fibronectin 
and observed an increase in SMC attachment by 11% in comparison to bare PU grafts 
after 8 hours [62]. In a separate study, Miller et al. modified poly(lactic-co-glycolic-acid) 
(PLGA) with NaOH for vascular graft applications and observed a 16% increase in SMC 
adhesion after 3 days over untreated PLGA scaffolds [213]. The results suggest that EM-
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23, which showed a 6000% increase in SMC adhesion over the controls, may be an 
extremely promising candidate for engineering vascular grafts. 
 Furthermore, cell spreading on PEG-RGDS, PEG-EM19, and PEG-EM23 grafted 
surfaces was quantified using ImageJ software. For all three peptides, cell area was a 
function of peptide concentration, and an increase in PEG-peptide concentration resulted 
in an increase in cell area. Although all peptides were able to stimulate cell spreading 
comparable to TCPS, EM-23 at the lowest concentration had a more significant impact 
on cell spreading than PEG-RGDS and PEG-EM19. This result suggests that the 
VGVAPG and the RGDS sequence in EM-23 synergistically serve to promote SMC 
spreading.   
Fluorescence staining was also used to quantify cell viability and visually 
characterize cell adhesion, spreading, and viability at different PEG-peptide 
concentrations. Cells on PEG-DA gels did not show any spreading and the staining 
protocol left no visible cells intact on the hydrogel surface. Cell viability was again found 
to have a similar trend when compared to cell spreading; an increase in PEG-peptide 
concentration increased the SMC viability. Visually depicting cell adhesion, viability, 
and spreading reconfirmed the initial characterization studies in which PEG-EM23 was 
found to have the most impact on the aforementioned phenomenon. This result is also 
consistent with previous work in which Gobin et al. achieved highest SMC spreading on 
a PEG-DA hydrogel surface modified with the VAPG peptide sequence at 5 mol/mL of 
PEG-peptide solution [86]. 
 Elastin deposition was quantified after 48 hours on PEG-DA surfaces modified 
with PEG-RGDS, PEG-EM19, PEG-EM19S, PEG-EM23, and PEG-EM23S at 5 mol. 
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Desmosine production was also quantified after 48 hours; however, the PEG chain 
heavily interfered with the desmosine ELISA (protocol discussed in Chapter 2), showing 
no feasible results. PEG-RGDS, PEG-EM19, and PEG-EM23S slightly increased elastin 
deposition while PEG-EM23 had comparable elastin deposition to TCPS. This result 
suggested that by utilizing the v3 integrins and the EBP receptors, EM-23 may be able 
to translate the complex mechanism of elastin fiber assembly to the PEG-DA surface.  
 
3.6 Conclusion 
The work in this chapter suggests that the synergy between v3 and the EBP in 
elastin fiber assembly may be translated and utilized in promoting SMC adhesion, 
spreading, viability, and elastin deposition on a synthetic substrate. These results further 
suggest that EM-23 may be a potential candidate for engineering viable vascular grafts 
because of its efficacy in increasing cell adhesion and elastin deposition. By utilizing key 
receptors, EM-23 is able to surpass an RGDS-based cell adhesive material to stimulate 





EM-23 as a 3D Template for Promoting Vascular ECM Deposition 
 
4.1 Summary 
 This chapter characterizes the capability of EM-23 to serve as a 3D template for 
promoting elastin production. EM-23 was conjugated to acrylate-PEG-N-
hydroxysuccinimide (PEG-NHS) to yield an acrylate-PEG-EM23-PEG-acrylate (PEG-
23-PEG) copolymer. The copolymer was crosslinked in the presence of a photoinitiator 
and UV light to form hydrogels comprised entirely of EM-23.  Moreover, a degradable 
sequence, (DS; AAAAAAAAAK), was also engineered and conjugated to PEG-NHS to 
allow for matrix remodeling over time in the presence of SMCs. Characterization studies 
were conducted on various combinations of PEG-23-PEG, PEG-DS-PEG, and PEG-DA. 
The 3D characterization discussed in this chapter suggested that EM-23 is a promising 
template for promoting elastin production in 3D over time, while also allowing scaffold 
remodeling and increased mechanical properties. Chapters 2 and 3 of this thesis discussed 
in detail the efficacy of EM-23 to promote and translate the complex mechanism of 
elastin fiber assembly to a synthetic construct. 
 
4.2 Introduction 
 Hydrogels are a swollen network of polymer crosslinks that serve as 3D ECM 
mimics, and tailoring them with a bioactive moiety can provide a suitable 
microenvironment for cell growth [67, 73]. Specifically, PEG-DA hydrogels were chosen 
as the synthetic material for vascular graft applications because of their ability to fine-
tune their mechanical properties by simply changing the molecular weight of the PEG 
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chains [23, 82, 84-86, 214]. Although, PEG-DA hydrogels lack the capabilities to 
promote ECM deposition, they can be easily tailored with bioactive moieties that 
promote ECM deposition and cell growth [82, 86, 206]. Previous work has also shown 
that PEG-DA (MW 10 kDa) at a concentration of 10 wt% in solution possesses the 
correct mesh size for vascular graft applications [81]. As such, hydrogels comprised of 
EM-23 were engineered to assess the ability of the peptide to promote ECM deposition in 
3D. Preliminary characterization suggested that EM-23 may serve as a potential template 
for promoting vascular ECM deposition in 3D and the results are indicative in suggesting 
EM-23 as a promising candidate for vascular graft applications. 
 
4.3 Materials and Methods 
4.3.1 Peptide Synthesis  
All materials and reagents required for peptide synthesis were purchased from 
AAPPTec (Louisville, KY). Peptides were synthesized using standard solid-phase 
peptide synthesis protocols [87, 88].  Briefly, four different peptides were synthesized 
using standard HBTU coupling and Fmoc protection chemistry on an Apex 396 peptide 
synthesizer (AAPPTec; Louisville, KY) using a lysine-conjugated Wang resin. A 23 
amino acid sequence (EM-23; AAKAAKVGVAPGRGDSAAKAAKK), containing two 
cell adhesion motifs (VGVAPG and RGDS) as well as lysine and alanine -rich 
crosslinking domains, was synthesized along with a 23 amino acid control peptide in 
which the VGVAPG sequence is scrambled and the RGDS sequence is left intact (EM-
23S; AAKAAKVGVPAGRGDSAAKAAKK). Two additional control sequences were 
also engineered where the RGDS motif on EM-23 was changed to RGES (EM-23SR; 
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AAKAAKVGVAPGRGESAAKAAKK) and the VGVAPG and RGDS motifs were 
collectively scrambled and changed to VGVPAG and RGES, respectively (EM-23X; 
AAKAAKVGVPAGRGESAAKAAKK). All control sequences, EM-23S, EM-23SR, and 
EM-23X, were engineered to evaluate the importance of VGVAPG and RGDS to 
promote elastin fiber assembly in 3D. Moreover, a degradable sequence (DS; 
AAAAAAAAAK) was also engineered to help remodel the hydrogel matrix. Crude 
peptides were then cleaved from the resin with cleaving cocktail (95% trifluoroacetic 
acid, 2.5% water, 2.5% triisopropylsilane) and purified by dialysis using cellulose ester 
membrane tubing (MWCO 1000; Spectrum laboratories, Rancho Dominguez, CA).  The 
dialyzed peptides were then frozen and lyophilized overnight.  Peptides were 
characterized using mass spectrometry.  
4.3.2 Cell Culture and Maintenance 
 Human aortic smooth muscle cells (SMCs, passages 3-5; Invitrogen Inc., 
Carlsbad, CA), were used.   SMCs were maintained in Medium 231 (Invitrogen Inc., 
Carlsbad, CA) supplemented with smooth muscle cell growth supplement (SMGS, 
Invitrogen Inc., Carlsbad, CA), 2 mM L-glutamine, 1 unit/ml penicillin, and 100 mg/l 
streptomycin (GPS; Cellgro, Manassas, VA) at 37°C in a 5% CO2 environment. 
4.3.3 PEG-DA Synthesis 
Synthesis of PEG-DA was conducted using well established protocols [81, 87, 88, 
209, 215].  PEG-DA was synthesized by dissolving 24 g dry PEG (MW: 10000; Fluka, 
Milwaukee, WI) in 20 ml anhydrous DCM with an equimolar amount of triethylamine 
and 0.869 g acryloyl chloride (Lancaster Synthesis, Windham, NH) added dropwise.  The 
mixture was stirred under argon for 24 hours, washed with 2M K2CO3, and separated into 
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aqueous and DCM phases to remove HCl.  The mixture was then centrifuged at 2,000×g 
for 1 hour and the aqueous phase aspirated and discarded. PEG-DA was then precipitated 
in diethyl ether, filtered, and dried under vacuum at room temperature overnight.  The 
resulting polymer was dialyzed overnight against DI water with 5 kDa MWCO cellulose 
ester tubing (Spectrum Laboratories, Rancho Dominguez, CA) to remove any residual 
salts. 
4.3.4 Synthesis of PEG-peptide Copolymers 
 Each peptide was conjugated to acrylate-PEG-N-hydroxysuccinimide (PEG-NHS, 
MW 5 kDa; Jenkem Technology, Allen, TX) in 50 mM sodium bicarbonate butter (pH 
8.5) at a 1:2 mole ratio for 2 hours (protected from light and under Argon) to yield a 
PEG-peptide-PEG copolymer. The final molecular weight of the copolymer was 
approximately 12 kDa. The mixture was then dialyzed (10000 MWCO dialysis cassettes; 
Pierce Biotechnology, Rockford, IL) against deionized water for 2 hours, lyophilized, and 
stored at –80C.  UV-Vis spectroscopy and GPC equipped with UV and ELS detectors 
(Agilent Technologies, Inc., Santa Clara, CA) were used to determine the coupling 
efficiency. The final PEG-peptide-PEG moiety was also characterized via mass 
spectrometry. 
Control peptides, EM-23S, EM-23SR, and EM-23X, were also reacted at a 1:2 
mole ratio with PEG-NHS in the manner described above. The control peptides have 
different binding motifs that are scrambled and were included to observe the importance 
of VGVAPG and RGDS in promoting elastin fiber assembly in 3D. Mass spectrometry 
results indicated that one mole of PEG-NHS reacted with DS or EM-23S while no 
detectable reaction occurred between the polymer and EM-23SR, or EM-23X (See 
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Appendix, Figures A.4, A.5, A.6, and A.7). A possible explanation for this observation is 
that the abundant alanine domains in DS and scrambled domains in the control peptides 
may be forcing the peptide to fold into different conformations while in solution. 
Although a reaction between PEG-NHS and the control peptides may be occurring to a 
certain extent, but to a lesser degree than EM-23. 
4.3.5 Hydrogel Degradation Studies 
 Hydrogels with different combinations of PEG-23-PG, PEG-DS-PEG, and PEG-
DA were synthesized, and their ability to degrade in the presence of elastase, one of 
many enzymes that cleave elastin, was evaluated. Four different polymer combinations 
were made and are listed in Table 4.1. The first polymeric gel, A, consisted entirely of 
PEG-23-PEG while the second combination, B, consisted of an even mixture of PEG-23-
PEG and PEG-DS-PEG. The third, C, and fourth, D, polymer combinations consisted of 
different ratios of PEG-23-PEG, PEG-DS-PEG, and PEG-DA. The different polymeric 
combinations were kept at 10 wt% in solution.  
Each combination was dissolved in 10 mM HEPES buffer (pH 7.4) followed by 
the addition of 10 l/mL of the photoinitiator DMAP (Alfa Aesar, Ward Hill, MA) in 
NVP (300 mg/mL). This precursor solution was added to FlexWell incubation chambers 
(Grace Bio-Labs, Bend, OR) and subsequently polymerized via UV light for 1 min (365 






Table 4.1. Four different hydrogel formulations were made comprised of varying ratios of PEG-
23-PEG, PEG-DS-PEG, and PEG-DA. The final copolymer concentration was kept at 10 wt%. 
 
 
Ratios of Each Polymer 
Formulation PEG-23-PEG PEG-DS-PEG PEG-DA 
A 100 0 0 
B 50 50 0 
C 50 30 20 
D 50 10 40 
 
The polymerized hydrogels were carefully transferred to glass vials and their 
initial weights were measured. Different concentrations of porcine pancreatic elastase 
(Elastin Productions Company, Owensville, MO) in PBS at 0.1, 1, and 2 mg/ml were 
added to the samples and placed in a 37ºC incubator. After each time point, the enzyme 
solution was aspirated, the gels were rinsed thoroughly with PBS, and the hydrogel 
weight was measured. The gels were again replenished with fresh enzyme solution. As 
controls, each polymer combination was incubated with only PBS and the hydrogel 
weights were measured in a similar manner described above. 
4.3.6 Cell Encapsulation  
 Each polymeric gel formulation was dissolved in 10 mM HEPES buffer (pH 7.4) 
and sterile-filtered using 0.2-μm pore size nylon filters (Pall Life Sciences, Port 
Washington, NY).  To these solutions, SMCs at a concentration of 250,000 cells/mL 
were added, followed by the addition of 10 l/mL of the photoinitiator DMAP (Alfa 
Aesar, Ward Hill, MA) in NVP (300 mg/mL). These precursor solutions were added to 
FlexWell incubation chambers (Grace Bio-Labs, Bend, OR) and subsequently 
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polymerized via UV light for 1 min (365 nm, 10 mW/cm2), yielding gels that were 6.8 
mm wide and 3 mm thick. The gels were thoroughly rinsed with PBS and carefully 
transferred to a 24 well plate and incubated with media. SMC media was replenished 
every 2 days. Rat tail type I collagen (BD Biosciences, San Jose, California) was used as 
a positive control. The acidic collagen solution was neutralized using sterile 1 M NaOH 
and combined with enough SMC media and PBS such that the final collagen 
concentration would be at 2 mg/mL. To this solution, SMCs at 250,000 cells/mL were 
added and the collagen gel was allowed to polymerize for 1 hour in a 37ºC incubator, 
which physically encapsulated the SMCs. SMC media was added after the collagen 
gelled completely and the media was replenished every 2 days. Similar polymeric gel 
formulations with the control PEG-peptide-PEG copolymers were also made. However, 
the control copolymers, PEG-23S-PEG, PEG-23SR-PEG, and PEG-23X-PEG, only 
gelled at the last polymer combination (i.e. the 50:10:40 ratio), and hence this 
formulation was used for all control experiments. PEG-DA gels as well as SMC 
encapsulated PEG-DA gels further served as controls. 
4.3.7 Biochemical Analysis of PEG-peptide-PEG hydrogels 
 After 2, 7, 14, and 21 days, elastin and collagen content were quantified. At each 
time point, the media was removed and rinsed with PBS. The gels were hydrolyzed with 
0.1 N NaOH for 24 hours in a 37ºC incubator. The samples were then transferred to a 
100°C oven for 2 hours to further solubilize ECM matrix proteins other than elastin.  The 
digested samples were centrifuged at 8,000×g for 10 min; the resultant pellets and 
supernatant were subjected to analysis for elastin and collagen content, respectively. 
 79
 The amount of elastin in the resulting pellet after the initial hydrolysis was 
determined using the Ninhydrin reagent.  The collected protein pellets were further 
subjected to acid hydrolysis using 6 N HCl at 100°C for 24 hours.  The digested samples 
were then neutralized, freeze-dried, and resuspended in 1 mL sodium citrate buffer (0.1 
M, pH 5.0).  To this suspension, 1 ml of Ninhydrin reagent (Spectrum Chemicals, New 
Brunswick, NJ) was added.  The reaction mixture was immersed in boiling water for 15 
mins, allowed to cool, and sample absorbances were read at 570 nm.  A standard curve 
comprised of known concentrations of soluble -elastin in sodium citrate buffer (0.1 M 
pH 5.0) was used to determine the elastin content of each sample.   
 The resulting supernatant from the digested samples were subjected to further 
hydrolysis with 6 N HCl at 110ºC for 24 hours. The hydrolyzed samples were 
neutralized, freeze-dried, and resuspended in 1 mL deionized water. Each sample was 
then reacted with 69 mM chloramine-T-hydrate (Sigma, St. Louis, MO) at room 
temperature for 20 mins. The reaction was quenched with 1.17 M (4-
dimethylamino)benzaldehyde (Sigma, St. Louis, MO) for 30 mins at 60ºC and allowed to 
cool to room temperature. Sample absorbances were read at 570 nm and hydroxyproline 
(Sigma, St. Louis, MO) served as a positive control. Total collagen content can be 
indirectly estimated as 1 mg of hydroxyproline is equivalent to 8 mg of collagen [216]. 
4.3.8 Hydrogel Compression Testing 
 Compression testing on each gel formulation was also conducted over a period of 
21 days. Initially, the gels were made into 1 mm thick molds intended for tensile tests. 
However, due to the inherent weakness of the 100% PEG-23-PEG gel, it could not be 
mounted properly to conduct tensile tests. Hence, thicker gels were made and the 
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compressive modulus was determined over a course of 21 days. Gel formulations A, B, 
and C were chosen for compression testing as they had the greatest effect on stimulating 
elastin production. The control gel, EM-23X-D, was also included in compression tests 
because this gel showed elastin production even though no adhesive sequences are 
present on the peptide sequence.  
Each gel formulation was made in the manner described previously in 10 mM 
HEPES buffer (pH 7.4), and sterile-filtered using 0.2-μm pore size nylon filters (Pall Life 
Sciences, Port Washington, NY).  To this solution, SMCs at a concentration of 250,000 
cells/mL were added, followed by the addition of 10 l/mL of the photoinitiator DMAP 
(Alfa Aesar, Ward Hill, MA) in NVP (300 mg/mL). This precursor solution was 
transferred to a 48 well plate and subsequently polymerized under UV light for 1 min 
(365 nm, 10 mW/cm2). The gels were then rinsed thoroughly with PBS, transferred to a 
24 well plate, and incubated with SMC media. The media was replenished every 2 days. 
Collagen gels served as a positive control and SMCs were encapsulated within the 
collagen gels in the manner described previously. 
 After each time point, the gels were rinsed with PBS and mounted on a BOSE 
EnduraTEC ELF 3200 Axial Testing System (EnduraTEC Systems Corporation, 
Minnetonka, MN). The gels were then subjected to compression with a load cell of 4.9 N 
at a compression rate of 0.25 mm/sec until failure. A stress-strain curve for each gel was 





                                                                                                                   (1) 
                                                                                                            (2) 
The strain () generated for each sample was determined by taking the difference in 
initial (l0) and final (l) thickness and dividing it by the initial thickness (Equation 1). The 
stress, on the other hand, was determined by taking the force (F) generated at each 
displacement and dividing it by the initial surface area (Ao) of each gel (Equation 2). The 
stress and strain corresponding to each displacement and force was tallied and a stress-
strain curve was generated for each gel. From each curve, the slope of the linear portion 
was determined to be the compressive modulus. 
4.3.9 Cell Viability  
 Cell viability in gel formulations A, B, C, and EM-23X-D was also assessed using 
a Live/Dead assay (Invitrogen Inc, Carlsbad, CA) after 7 and 21 days. Each gel 
formulation was made in the manner described above in 10 mM HEPES buffer (pH 7.4) 
and sterile-filtered using 0.2-μm pore size nylon filters (Pall Life Sciences, Port 
Washington, NY).  To this solution, SMCs at a concentration of 250,000 cells/mL were 
added followed by the addition of 10 l/mL of the photoinitiator DMAP (Alfa Aesar, 
Ward Hill, MA) in NVP (300 mg/mL). This precursor solution was injected between two 
glass slides separated by a 400-m spacer (Thermo Scientific, Asheville, NC) and 
subsequently polymerized via UV light (365 nm, 10 mW/cm2). The top glass slide was 
carefully lifted, the polymerized gel sheet was rinsed thoroughly with PBS, and 10 mm 
diameter gel samples were carefully cut and transferred to a 24 well plate. SMC media 
was then added and replenished every 2 days. 
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 After days 7 and 21, the media was removed, and gels were rinsed with PBS. The 
gels were then incubated with a solution containing 2 M calcein AM and 4 M ethidium 
homodimer-1 for 25 mins at 37°C. The gels were then mounted onto a cover slide and 
imaged using a Zeiss LSM 510 VIS confocal microscope (Carl Zeiss Microscopy, 
Thornwood, NY). Initially a 200-m spacer was utilized to make thin flat gels for 
confocal microscopy. However, the 100% PEG-23-PEG gels were extremely weak and 
fell apart. As a result, gels were made using the 400-m spacer. 
4.3.10 Statistical Analysis 
All experiments were performed minimally in triplicate.  Error bars indicate 
standard deviation, and statistical analysis was performed using a single factor ANOVA; 
p-values < 0.05 were considered to be significant. Moreover, to determine statistical 
significance between sample sets for the compression data, a Kruskal-Wallis 
nonparametric ANOVA test was used. The nonparametric test does not assume the data 
to be normally distributed and the test is instead performed on ranked data. This allows 





4.4.1 Gel Degradation in the Presence of Elastase 
 
In the absence of elastase, each hydrogel formulation continued to swell well past 
10 hours (Figure 4.1). However, the different types of gels degraded at different rates in 
the presence of elastase. Gel formulation A completely degraded within 24 hours for each 
elastase concentration, whereas gel formulation B showed faster degradation kinetics by 
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completely degrading within 10 hours. On the other hand, gel formulations C and D did 
not degrade at any elastase concentration and instead swelled over time. This result 
suggests that elastase is only able to breakdown the EM-23 and DS components within 
gels C and D, while the PEG-DA component remained intact. As the peptides are 
degraded in these gels, more water diffuses into the construct, causing increased swelling.  
Figure 4.1. Gel degradation curves in the presence of elastase at 0 (A), 0.1 (B), 1 (C), and 2 (D) mg/ml. 
Gel formulation B degrades the most out of all the other formulations at each enzyme concentration (n = 3). 
 
4.4.2 Elastin Content in Peptide Polymerized Hydrogels 
 In the presence of collagen gels, levels of elastin detected were 78 ± 27, 43 ± 24, 
38 ± 27, and 208 ± 56 g at days 2, 7, 14, and 21, respectively (Figure 4.2). Gel 
formulation A had levels of 42 ± 7, 42 ± 8, 99 ± 16, and 219 ± 21 g at days 2, 7, 14, and 
21, respectively. Similarly, gel formulation B had elastin levels of 44 ± 7, 53 ± 14, 85 ± 
6, and 192 ± 26 g at days 2, 7, 14, and 21, respectively. Gel formulation C had elastin 























































































Finally, in the presence of gel formulation D, elastin levels detected were 18 ± 5, 25 ± 2, 
139 ± 11, and 142 ± 14 g at days 2, 7, 14, and 21, respectively. 
 
Figure 4.2. Elastin content over the course of 21 days in the presence of different PEG-peptide-PEG 
hydrogels. Gel formulations A, B, C, and D showed comparable elastin production to the positive control 
of collagen gels after 21 days. The control peptides did not have comparable elastin production to collagen 
nor the experimental conditions after 21 days. (n=3-5, *p < 0.05 from Collagen; **p < 0.05 from gel 
formulation A; η p < 0.05 from gel formulation B). 
 
No statistical significance in elastin production was found between collagen gels 
at day 21 from gels of A, B, C, and D. However, elastin production was statistically 
significant between gel A and gels C as well as D. Moreover, elastin production from 
gels B and D were also statistically significant. Also, from the data presented in Figure 
4.1A, the weight of each gel can be approximated to be 0.2 g. Therefore, for each 
hydrogel, the total elastin content can also be estimated in terms of g of elastin per mg 
of scaffold where after 21 days, elastin content per mg of scaffold is approximately 1 ± 
0.1, 1 ± 0.13, 0.8 ± 0.07, and 0.6 ± 0.3 g elastin/mg of scaffold in gel formulations A, B, 
C, and D respectively. 
 Further, the control gel formulations EM-23S-D, EM-23SR-D, and EM-23X-D, 
had elastin production of only 48 ± 19, 27 ± 20, and 69 ± 9 g after 21 days. Elastin 
production was still observed in gels comprised of EM-23X, although no adhesive motifs 
are present in the peptide. This phenomenon may be a result of SMCs being trapped 
































Previous work has suggested that the least cell adhesive sequence grafted onto the surface 
of a PEG-DA hydrogel yields the highest ECM deposition, and this phenomenon may 
translate to this 3D model [205]. 
4.4.3 Hydroxyproline Content  
 For each PEG-peptide-PEG gel, the overall hydroxyproline content decreased 
over time, suggesting collagen degradation by SMCs (Figure 4.3). Quantifying total 
hydroxyproline content is an indirect estimation of total collagen content, as 1 mg of 
hydroxyproline is equivalent to 8 mg of collagen. In the presence of gel formulation A, 
hydroxyproline content detected at days 2, 7, 14, and 21 were 0.06 ± 0.01, 0.17 ± 0.03, 
0.18 ± 0.02, and 0.12 ± 0.03 g, respectively. Hydroxyproline content at days 14 and 21 
were not significant from each other even though the hydroxyproline levels detected 
decreased by ~0.05 g. Gel formulation B contained 0.22 ± 0.02, 0.18 ± 0.05, 0.21 ± 
0.04, and 0.14 ± 0.003 g of hydroxyproline at days 2, 7, 14, and 21, respectively. 
 
Figure 4.3. Hydroxyproline content in the presence of PEG-peptide-PEG hydrogels. Total collagen content 
can be indirectly calculated by dividing the amount of hydroxyproline content by 0.13. In each hydrogel 
formulation, hydroxyproline content decreased over time, suggesting collagen degradation. (n = 3-5; *p < 




































A similar trend was also observed with gel formulation C; total hydroxyproline 
content detected was 0.11 ± 0.04, 0.10 ± 0.05, 0.17 ± 0.04, and 0.06 ± 0.03 g at days 2, 
7, 14, and 21, respectively. Finally, gel formulation D had a large increase of 0.15 ± 
0.004 g hydroxyproline observed at day 2 and the levels of hydroxyproline continuously 
decreased at days 7, 14, and 21 (hydroxyproline levels detected were 0.09 ± .016, 0.09 ± 
0.03, and 0.03 ± 0.008 g after days 7, 14, and 21, respectively). Hydroxyproline levels 
detected at day 2 and 21 were statistically significant from each other in all gel 
formulations except C (although gel C shows a similar trend of decreasing 
hydroxyproline content over time). 
 The control gel formulations also showed a similar trend as the experimental 
conditions. In the presence of the EM-23S-D gel formulation, hydroxyproline levels 
detected were 0.08 ± 0.07, 0.04 ± 0.006, 0.05 ± 0.04, and 0.06 ± 0.01 g at days 2, 7, 14, 
and 21, respectively. On the other hand, no hydroxyproline content was detected at day 2 
for either EM-23SR-D or EM-23X-D gel formulation. In the presence of EM-23SR-D, 
total hydroxyproline detected was 0.15 ± 0.01, 0.06 ± 0.04, and 0.09 ± 0.01 g at days 7, 
14, and 21, respectively. Finally, hydroxyproline content in the presence of EM-23X-D 
gels was 0.09 ± 0.02, 0.16 ± 0.02, and 0.04 ± 0.01 g at days 7, 14, and 21, respectively. 
4.4.4 Estimating the Compressive Modulus of Different PEG-peptide-PEG Hydrogels 
The compressive modulus of blank 10 kDA PEG-DA at 10 wt% was determined 
to be 106 ± 5 kPa (Figure 4.4). Collagen gels, which served as a positive control, showed 
an increased in compressive Young’s Modulus over a course of 21 days (the compressive 
Young’s Modulus calculated was 7 ± 2, 7 ± 0.2, 7 ± 1, 12 ± 2, and 13 ± 2 kPa at days 0, 
2, 7, 14, and 21, respectively). 
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Figure 4.4. Estimated compressive modulus of different gel combinations over a course of 21 
days. After 21 days of SMC culture, the linear Young’s Modulus of each gel combination except EM-23X-
D significantly increased from day 0. (n = 3-4; *p < 0.05 from day 0 of each condition). 
 
The compressive modulus for gel formulation A was 118 ± 2, 124 ± 2, 122 ± 13, 139 ± 
14, and 138 ± 1 kPa at days 0, 2, 7, 14, and 21, respectively. Similarly, the compressive 
modulus for gel formulation B increased over time and was determined to be 120 ± 5, 
136 ± 5, 143 ± 3, 146 ± 4, and 167 ± 8 kPa at days 0, 2, 7, 14, and 21, respectively. 
Finally, the compressive modulus for gel formulation C was 127 ± 3, 137 ± 6, 139 ± 5, 
132 ± 4, and 147 ± 12 kPa at days 0, 2, 7, 14, and 21 respectively. Gel C showed a higher 
elastin production than D and hence was chosen for compression testing over gel D 
(Figure 4.2). The compressive modulus for gel A, B, C, and collagen were statistically 
significant from day 0 and 21. 
 The compressive Young’s Modulus for the control gel formulation, EM-23X-D, 
was 128 ± 1, 128 ± 2, 127 ± 2, 127 ± 2, and 128 ± 2 kPa at days 0, 2, 7, 14, and 21 







































day 0 and days 2, 7, 14, and 21 suggesting that the presence of elastin in this control gel 
may be a result of cells being trapped inside the gel, triggering some ECM formation. 
4.4.5 Cell Viability in PEG-peptide-PEG Hydrogels 
 After 7 and 21 days, SMC viability within the hydrogel formulations of A, B, and 
C were visually confirmed (Figure 4.5).Visual confirmation of SMC viability over time 
suggests that the different gel formulations are capable of providing a suitable 
microenvironment for cell adhesion over time. The control sequence, EM-23X-D, on the 
other hand did not contain viable cells, which was confirmed by only red fluorescence.  
 
Figure 4.5. SMC viability in the presence of different gel formulations at days 7 and 21. Gel formulations 
A, B, and C had live cells at days 7 and 21 whereas the control gel, EM-23X-D did not show any cell 




 The studies detailed in this chapter evaluate the efficacy of EM-23 to promote 
vascular ECM deposition within a 3D construct for potential vascular graft applications. 
As such, EM-23 was reacted at a 1:2 mole ratio with PEG-NHS to yield a diacrylated 
PEG-23-PEG copolymer. The acrylate groups on either end of the copolymer crosslinked 
to form a 3D hydrogel comprised entirely of EM-23. Moreover, PEG-NHS at 5 kDa was 
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chosen in order to ensure that the final molecular weight of the copolymer would be close 
to 10 kDa. Previous studies have confirmed that 10 kDa PEG-DA hydrogels fabricated at 
10 wt% are optimum for vascular graft applications [23, 214].  
Munoz-Pinto et al. achieved the highest amounts of elastin and collagen 
production in the presence of SMCs encapsulated with RGDS and 10 kDa PEG-DA 
hydrogels at 10 wt% in comparison to 20 and 30 wt% [84]. Several other studies have 
also shown that 10 kDa PEG-DA hydrogels at 10 wt% possess the optimum mesh size for 
nutrient transport [81, 214]. Therefore, EM-23 was reacted with PEG-NHS at a 1:2 mole 
ratio to yield a diacrylated product that would be close to 10 kDa (although mass 
spectrometry analysis suggested that the actual molecular weight was closer to 12 kDa; 
see Appendix, Figure A.3). A degradable sequence, DS (AAAAAAAAAK), was also 
reacted with PEG-NHS at a 1:2 mole ratio to yield a PEG-DS-PEG copolymer. This 
specific sequence is an elastase cleavable sequence, and hence incorporating this 
copolymer within the 3D construct would be beneficial to allow for ECM remodeling 
over time [73, 206]. 
 Four different gel formulations were made that consisted of varying amounts of 
PEG-23-PEG, PEG-DS-PEG, and PEG-DA. The first formulation, A, consisted entirely 
of PEG-23-PEG whereas the second formulation, B, consisted of an even mixture of 
PEG-23-PEG and PEG-DS-PEG. The third formulation, C, consisted of a 50:20:30 ratio 
of PEG-23-PEG:PEG-DS-PEG:PEG-DA while the last formulation, D, consisted of a 
50:10:40 ratio of PEG-23-PEG:PEG-DS-PEG:PEG-DA. All of the aforementioned 
formulations were maintained such that the final copolymer concentration would be at 10 
wt%.  
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 Different gel formulations were investigated for their ability to degrade over time 
in the presence of the cell secreted enzyme elastase. The ability of the gel to degrade can 
be indicative of how well the cell-deposited ECM can be remodeled during long-term 
culture. Hence, degradation rates for each gel formulation were determined in the 
presence of different elastase concentrations.  Of note, the elastase concentrations used 
for this study were much higher than physiological concentrations [217]. However, the 
higher concentrations allowed for rapid investigation of hydrogel behavior. Gel 
formulation A, which consisted entirely of PEG-23-PEG, completely degraded in the 
presence of elastase within 24 hours. Elastase has been shown to cleave a di-alanine 
amino acid block (i.e. AA) and hence the enzyme was able to cleave EM-23 due to the 
presence of abundant di-alanine amino acid blocks in the crosslinking moieties of EM-23 
[218, 219]. This result also suggests that hydrogels comprised entirely of EM-23 can 
degrade in addition to promoting vascular ECM deposition. Further, gel formulation B 
degraded completely within 10 hours in the presence of each elastase concentration. This 
phenomenon is likely due to the abundance of di-alanine blocks available in the DS and 
EM-23 sequences.  
On the other hand, gel formulations C and D did not degrade and instead showed 
an increased swelling behavior over time. A possible explanation lies in the ability of 
elastase to cleave EM-23 and DS, but not the PEG-DA chains. The data suggests that in 
both C and D gel formulations, the structural integrity of the gels remained intact due to 
the presence of PEG-DA. As more PEG-23-PEG and PEG-DS-PEG chains degraded, the 
mesh size of the hydrogel increased, allowing for increased diffusion of water into each 
construct. This phenomenon resulted in hydrogel swelling instead of degradation, and the 
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data further suggested that the swelling occurs until equilibrium is reached. Moreover, 
this data may also imply that ECM remodeling by cells encapsulated within gels C and D 
could reach a threshold at which PEG-DA chains become the dominant copolymer within 
the construct.  
Further, elastin content in the presence of SMCs was also quantified within the 
four different gel formulations over a course of 21 days. Rat tail collagen type I was used 
as a positive control. Elastin content in collagen gels decreased from days 2 to 14, while 
steeply increasing at day 21. SMCs secrete matrix metalloproteinase-2 (MMP-2) and 
MMP-9 which actively degrade collagen gels [220-222]. For example Kanda et al. 
demonstrated SMC invasion through collagen type I lattice by degrading the collagen 
fibers via MMP-2 and MMP-9 [223]. The current data suggests that once SMCs were 
encapsulated, the cells degraded the collagen, compacting it over time and the SMCs 
eventually migrated from the gel to the TCPS surface. Hence, elastin production at days 7 
and 14 was lower in comparison to day 2. At day 21, however, most of the gel was 
completely degraded and a majority of the cells had migrated from the gel and adhered to 
TCPS. The elastin levels detected likely resulted from all the cells adhered to TCPS; 
elastin content was also quantified for SMCs seeded on TCPS over 21 days and the total 
elastin content at day 21 was similar to elastin content from the degraded collagen gels at 
day 21.  
Moreover, gel formulations A, B, C, and D continuously increased elastin 
deposition over a course of 21 days, and elastin content at day 21 was comparable to 
elastin content in collagen gels. These results suggest that the gel formulations are able to 
promote elastin deposition over long culture times. In comparison, Ramamurthi et al. 
 92
engineered hyaluronic hydrogels to promote elastin deposition over time. After 4 weeks 
of static culture, the hyaluronic gels promoted elastin levels that were similar to TCPS, 
however, a majority of the elastin detected was uncrosslinked and immature [224]. 
Similarly, Venkataram et al. attempted to stimulate elastin deposition in hyaluronic gels 
with the addition of transforming growth factor-beta1 (TGF-1). However, the gels 
showed poor elastin deposition over the course of 3 weeks [225]. The studies detailed in 
this chapter suggest that hydrogels comprised of EM-23 can promote elastin deposition 
over time without the addition of different growth factors. Also, Lee et al. reported values 
of approximately 90 g of elastin per mg of carotid artery tissue [226]. As an 
approximation, the results suggested in this chapter indicate that the total elastin content 
measured was only 1% of the total elastin content found in a native artery. However, the 
increase in elastin production over 21 days in gels containing EM-23 is highly indicative 
of the peptide’s ability to promote elastin deposition. 
The control gel formulations contained elastin levels of approximately half of the 
total elastin content detected at day 21 in gel formulations A, B, C, and D. The gel 
formulation EM-23X-D showed elastin production over 21 days even though no cell 
adhesive motifs are present in EM-23X. This result may be due to SMC entrapment 
within the gel and in an effort to adhere inside the gels, the cells may be secreting ECM 
proteins, causing elastin detection.  
Hydroxyproline content was also quantified over a course of 21 days in the 
different gel formulations, including the control copolymers. The amount of 
hydroxyproline decreased over time within all gel formulations suggesting that 
significant collagen remodeling may be occurring. As mentioned above, SMCs secrete 
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active MMP-2 and MMP-9 that continuously degrade collagen and this phenomenon may 
further help support the decrease in total hydroxyproline content over time. Moreover, in 
comparison to elastin, collagen is more susceptible to degradation and this effect may be 
manifesting within the different gels [227].  
As further characterization, the compressive modulus for gel formulations A, B, 
C, and EM-23X-D was determined over a course of 21 days. Collagen gels were again 
used as the positive control. Initially, the hydrogels were made in 1 mm thick molds 
intended for tensile tests. However, the gels were too weak and compressive testing was 
instead done on thicker gels. It should be noted that compressive testing is not as accurate 
as tensile testing because as the material is compressed, the surface area of that material 
changes and becomes a function of the force applied on the material. However, previous 
studies have confirmed that the compressive modulus of 10 kDa PEG-DA hydrogels at 
10 wt% is similar to the measured tensile modulus [79, 84]. This result is likely due to the 
elastic nature of the PEG-DA hydrogels in the strain regime [79]. In addition, cells induce 
a significant amount of contractile forces during ECM remodeling, and compressive 
strength is an accurate estimation to determine the mechanical forces experienced by the 
cells over time [84]. 
The compressive modulus for 10 kDa PEG-DA hydrogels at 10 wt% was in 
excellent agreement with previously published results [84, 228, 229]. Collagen gels 
showed poor compressive modulus until days 14 and 21. The sharp increase in modulus 
after day 7 is likely a result of collagen degrading and compacting the final scaffold into a 
stiffer construct. All gel formulations except EM-23X-D showed a significant increase in 
the compressive modulus after 21 days. This phenomenon suggests that the increase in 
 94
compressive modulus could be a result of increased ECM deposition over time [83, 230]. 
As expected, no change in compressive modulus was observed in the control gel 
formulation, suggesting that the elastin detected within this gel type may be a result of 
cell entrapment, which triggers some ECM secretion. Comparatively, gel B had a larger 
compressive modulus increase between 0 and 21 days suggesting that increased ECM 
remodeling and deposition may be occurring within this gel.  
Moreover, the work presented in this chapter was conducted in static cultures. 
Previous studies have confirmed large differences in ECM deposition within scaffolds 
when subjected to static and dynamic conditioning [214, 221, 230]. For example, Song et 
al. fabricated vascular grafts from poly(trimethylene carbonate) scaffolds and 
dynamically conditioned them under physiological flow conditions resulting in a 
maximum tensile strength of 0.47 ± 0.06 MPa (compared to the tensile strength of a 
native artery of 1.55 ± 0.21 MPa) [231]. Moreover, Gao et al. fabricated vascular grafts 
from poly(glycerol sebacate) and after dynamically conditioning the grafts for 2 weeks, 
elastin and collagen deposited were visually comparable to native arteries, although no 
quantification of elastin content was reported [232]. In a separate study, Syedain et al. 
fabricated vascular grafts from fibrin, and after dynamically conditioning the grafts, 
significant improvement was found in mechanical strength over statically cultured grafts 
[233]. However, the compressive modulus observed for the different gels, except for EM-
23X-D, increased by almost 20% after 21 days in comparison to PEG-DA, suggesting the 
ability of EM-23 to facilitate ECM deposition over time. The increase in elastin 
production over time, in addition to the increase in compressive modulus over time, 
suggests that EM-23 is a promising candidate for vascular graft applications.  
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Cell viability within gel formulations A, B, C, and EM-23X-D was also visualized 
at days 7 and 21. As expected, cells were viable in gel formulation A, B, and C whereas 
EM-23X-D gels supported no viable cells. This result is in excellent agreement with the 
compression data and further reinforces the initial hypothesis of cell-secreted ECM in 
EM-23X-D hydrogels due to entrapment. The viability data also confirm that formulation 





 The engineered elastin mimetic peptide, EM-23, was further characterized as a 3D 
template for promoting vascular ECM deposition. The studies in this chapter indicate that 
EM-23 is capable of promoting ECM deposition in a 3D scaffold. Moreover, degradation 
studies suggested that hydrogels comprising of EM-23 can remodel over time, which 







5.1 Results and Implications 
 The work outlined in this thesis investigates the use of novel elastin mimetic 
peptides, EM-19 and EM-23, in promoting vascular ECM deposition for potential 
vascular graft applications. Step-by-step characterization studies were conducted on the 
peptide sequences to elucidate how each peptide interacted with SMC cultures, as well as 
the impact the peptides had on vascular ECM production. Moreover, the peptides were 
grafted on top of PEG-DA hydrogel surfaces, and EM-23 stimulated significant cell 
adhesion and comparable elastin production in comparison to TCPS. Furthermore, 3D 
hydrogels comprised of EM-23 were able to promote elastin deposition over time. The 
detailed conclusions will be discussed in the subsequent sections. 
5.1.1 EM-23 is a Promising Candidate for Vascular Graft Applications 
 Various characterization studies were conducted on different elastin mimetic 
peptides that could be used as templates for promoting vascular ECM deposition within a 
synthetic scaffold. The studies suggested that EM-23, containing an EBP binding motif 
and an integrin binding domain, is a promising candidate for vascular graft applications. 
The in vitro characterization of the peptides suggested that a synergistic mechanism may 
exist between the EBP and integrins in elastin fiber assembly. Specifically, the integrin 
v3 was suggested to play the synergistic role with the EBP in elastogenesis and it is 
beneficial to have the integrin binding domain in EM-23 to help translate the complex 
mechanism of elastin fiber assembly to a synthetic construct. 
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Once grafted onto the surfaces of PEG-DA hydrogels, EM-23 was able to 
facilitate significant SMC adhesion on PEG-DA in comparison to EM-19 and RGDS-
grafted surfaces. Moreover, EM-23 promoted elastin deposition comparable to TCPS, 
suggesting that the peptide may be utilizing the two different binding motifs to promote 
significant cell adhesion and elastin deposition on PEG-DA surfaces. The studies 
indicated that EM-23 is an extremely promising candidate for vascular graft applications. 
 As further characterization, different hydrogels comprised of EM-23, including an 
enzymatically cleavable sequence, DS, were also able to promote elastin deposition over 
time. Hydrogels containing only EM-23 degraded in the presence of elastase, suggesting 
that this peptide may serve as a remodeling and an ECM promoting template. To 
engineer a suitable vascular graft, it is important that the scaffold have the necessary cues 
that promote ECM deposition and remodeling over time. This allows the scaffold to 
create a suitable microenvironment for cell growth while providing adequate structural 
integrity to the scaffold. In addition, hydrogels with different ratios of EM-23, DS, and 
PEG-DA demonstrated gel swelling instead of degradation, a phenomenon caused likely 
due to water diffusing into the construct as EM-23 and DS are continuously degraded. 
The study further suggested that hydrogels comprised of EM-23, DS, and PEG-DA may 
reach a threshold in ECM remodeling over time. Moreover, a significant increase in the 
compressive strength was also observed in hydrogels containing EM-23 in comparison to 
PEG-DA hydrogels. The increase in mechanical strength was likely a result of increased 
ECM production and further reinforces the candidacy of EM-23 as a suitable substitute 
for engineering vascular grafts.  
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Current vascular graft technologies lack the ability to promote a viable vascular 
ECM leading to graft failure post implantation. The characterization studies described in 
this thesis suggest that EM-23 is a potential candidate to bridge the gap in ECM 
production within the engineered grafts. Although more studies are warranted, it is clear 
that EM-23 is a promising candidate for addressing the ongoing demands for engineering 
a suitable vascular graft substitute. As such, future characterization work will be 
discussed in the subsequent sections.   
 
5.2 Future Work 
 The following sections detail possible future work in further characterizing the 
ability of EM-23 to translate the complex mechanism of elastin fiber assembly to a 3D 
scaffold intended for vascular grafts. 
5.2.1 Further Characterization of EM-23 as a 3D template 
 As outlined in Chapter 4 of this thesis, EM-23 was conjugated with PEG-NHS at 
a 1:2 mole ratio to yield a diacrylated PEG-EM23-PEG copolymer. However, mass 
spectrometry results indicated that only 30% of the final product was the diacrylated 
moiety while the rest was comprised of the monoacrylated product. Hence, it is suggested 
that the reaction be conducted in a more controlled environment in which 2 moles of 
PEG-NHS are reacted with every mole of peptide. A controlled environment can be 
achieved within the peptide synthesizer, which conjugates peptides from the carboxyl to 
amine terminus (C- to N-terminus), used in the work for this thesis (Figure 5.1).  
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Figure 5.1. A proposed mechanism for fabricating a PEG-23-PEG moiety in a controlled manner. The N-
terminus of a peptide already coupled to a resin can be conjugated with PEG-NHS (A). After cleaving (B), 
the resulting product can be further conjugated with an amine based PEG moiety (C), where the product 
can then be reacted with 2 moles of acryloyl chloride to yield a diacrylated PEG-peptide copolymer (D). 
 
The N-terminus of the peptide conjugated to the resin can be coupled directly with one 
mole of PEG-NHS that does not bear an acrylate moiety. After cleaving the peptide off of 
the resin, the peptide-PEG copolymer can be reacted with an additional mole of PEG-
NH2 yielding a di-PEG peptide moiety. Acrylate groups can then be attached to either 
end of the PEG chains to yield a diacrylate moiety. Although optimization of the reaction 
conditions must be conducted, this protocol outlines the general procedure for controlling 
the diacrylation of peptides. 
Further, the 3D hydrogel results suggested that constructs made from EM-23 and 
the proteolytically cleavable peptide sequence, DS, may serve to be the ideal templates 
for promoting vascular ECM deposition. However, more in depth experiments must be 























translating elastin fiber assembly to a 3D construct. For example, in order to investigate 
the impact each gel formulation has on elastin crosslinking, tropoelastin and LOX mRNA 
levels should be quantified. Moreover, quantifying total DNA content within the gels can 
also help elucidate how much elastin is produced on a per cell basis. The results from 
these two experiments should reveal further insights on the mechanistic phenomenon of 
elastin fiber assembly in a 3D scaffold. 
5.2.2 Dynamic Mechanical Stimulation 
 The experiments in Chapter 4 of this thesis were all conducted under static 
culture. However, to fully investigate the ability of the different 3D templates to serve as 
potential vascular grafts, dynamic experiments that mimic physiological conditions must 
be conducted. Numerous studies have confirmed that large differences lie in ECM 
production and mechanical strength within synthetic constructs when subjected to a static 
or dynamic environment [81, 221, 230]. Physiological conditions can be mimicked by a 
bioreactor that simulates flow and culturing conditions of a biologically active 
environment (Figure 5.2). Along with providing the adequate environment, a bioreactor is 
also capable of delivering flow-mediated stresses to constructs, allowing for cell culture 
and growth in different mechanical conditions [234]. 
 Therefore, it is suggested that similar constructs to the ones discussed in Chapter 
4 be engineered in a tubular format with encapsulated SMCs and subjected to dynamic 
stimulation that mimics physiological conditions over a course of 21 days. For example, 
Syedain et al. fabricated vascular grafts from fibrin gels by developing a bioreactor and 
conditioning the constructs with physiological flow conditions over time [233]. After 9 
weeks of culture, the grafts were significantly remodeled and were able to achieve burst 
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pressures and compliance comparable to native arteries. However, the grafts lacked 
elastin deposition and did not have the circumferential cell alignment characteristic of the 
medial layer of a blood vessel. 
 
Figure 5.2. An example of a bioreactor that could be engineered in order to induce mechanical 
stimulations. 
 
 Cell alignment within the different 3D templates is also another key factor to 
consider for further studies. Within the medial layer of a blood vessel, SMCs and elastin 
fibers are circumferentially aligned, which synergistically provide the optimal 
compliance [3, 15]. Moreover, dynamic mechanical stimulation on synthetic grafts has 
been found to control the orientation of cells and the ECM deposited [230, 233, 235, 
236]. Therefore, in addition to dynamic conditioning of the different gel formulations 
containing EM-23, it is also suggested to design experiments that control cell alignment 
within the constructs. Constructs without conditioning or random cell orientation should 
be used as the appropriate controls. Furthermore, the inherent weakness of the hydrogels 
could limit the efficacy of engineering the constructs in a tubular format. Hence the 







modifying them with EM-23 in order to engineer robust tubular scaffolds is also 
suggested. 
5.2.3 Alternative Materials and Techniques for Engineering Vascular Grafts 
 Although PEG-DA hydrogels have been suggested to be the ideal material for 
vascular graft applications, their use is limited due to poor mechanical strength. 
Polyurethanes are an alternative class of material that have gained much interest in the 
past few years for vascular graft applications [10, 61, 63]. PU-based materials have been 
modified with bioactive moieties to facilitate cell adhesion and improve mechanical 
properties [26, 36, 62]. For example, Punshon et al. chemically combined PU with a 
nanocomposite fabricated from polyhedral oligomeric silsesquioxane and observed 
viscoelastic properties similar to native arteries [237]. Moreover, Jun et al. modified 
microporous PU scaffolds with PEG and a endothelial cell specific bioactive sequence, 
YIGSR (tyrosine-isoleucine-glycine-serine-arginine) and demonstrated increased 
endothelialization and improved mechanical properties [61]. As such, it is suggested that 
similar characterization studies that were conducted in this thesis be done on PU based 
materials modified with EM-23 and the results directly compared to the PEG based 
materials modified with EM-23.  
 Also, PLA and PGA are another class of materials routinely used for vascular 
graft applications [11, 26]. PLA materials allow for slower degradation rates whereas 
PGA based materials are highly biocompatible and biodegradable [42, 43, 53, 54]. For 
example, Kim et al. engineered vascular grafts from PLA based materials and found a 
significant improvement in elastin production after dynamically conditioning the grafts 
[56]. In a separate study, Niklason et al. engineered vascular grafts from PGA based 
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materials and found comparable burst pressures to saphenous veins after dynamically 
conditioning the grafts, although the grafts lacked the presence of elastin [48]. Combining 
either material with EM-23 can serve to bridge the gap in elastin production within these 
materials and potentially lead to engineering more compliant vascular grafts. 
 Additionally, electrospinning has gained considerable attention in the past five 
years as an alternative strategy in engineering vascular grafts [67, 238-242]. 
Electrospinning allows for precise control over fiber orientation and diameters, and 
allows for a higher area to volume ratio for cell attachment [33, 60, 241]. Combining 
different polymers such as PU, PLA, and PGA with EM-23 and electrospinning the 
copolymer solution into a tubular construct may assist in controlling cell adhesion and 
alignment in a specific manner, while achieving precise fiber orientation within the 
construct. The fabricated graft should further be mechanically conditioned under 
physiological flow and long term studies on ECM deposition and mechanical strengths of 
the graft should be investigated. 
 Although further characterization studies are clearly warranted, the work 
presented in this thesis describes the synthesis and characterization of a novel elastin 
mimetic peptide capable of promoting ECM deposition for vascular graft applications. 
Current vascular graft technologies lack the capability to promote ECM deposition. With 
the goal to engineer compliant vascular grafts, this thesis described the initial steps in 
designing and characterizing a suitable material that can promote vascular ECM 
deposition within a synthetic scaffold. The future work suggested will further assess the 
capability of EM-23 to translate the complex mechanism of elastin fiber assembly to an 




Figure A.1. Elution times of various PEG-peptide copolymers. A characteristic tetrahydrofuran solvent 




Figure A.2. Extrapolated molecular weights for the different PEG-peptide copolymers. The determined 
molecular weight for PEG-EM19 and PEG-EM19S was 5500 Da while PEG-EM23 and PEG-EM23S has a 
molecular weight of 5700 Da. These molecular weights confirm successful conjugation of the peptide with 














Figure A.3. Mass spectrometry results of conjugating EM-23 with PEG-NHS at a 1:2 mole ratio. Only 
30% of the total final product showed the expected molecular weight. 
 
 
Figure A.4. Mass spectrometry results of conjugating EM-23S with PEG-NHS at a 1:2 mole ratio showing 
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Figure A.5. Mass spectrometry results of conjugating DS with PEG-NHS at a 1:2 mole ratio showing trace 
amounts of the expected product. 
 
  




























































































Figure A.7. Mass spectrometry results of conjugating EM-23X with PEG-NHS at a 1:2 mole ratio. 
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